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CLINICAL PREDICTORS OF DRUG RESISTANCE AND MORTALITY AMONG TUBERCULOSIS 
PATIENTS IN A RURAL SOUTH AFRICAN HOSPITAL: A CASE-CONTROL STUDY
Jason R. Andrews, Neel R. Gandhi, Anthony P. Moll, Gerald H. Friedland. Yale AIDS Program, 
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
The recent discovery of a high prevalence of multidrug-resistant (MDR-TB) and 
extensively drug-resistant tuberculosis (XDR-TB) in rural South Africa, where HIV is rampant, 
has provoked alarms about the future of tuberculosis control in the region.  Little is known about 
the clinical manifestations of MDR-TB in general, and XDR-TB in particular, in the high HIV
prevalence settings of Sub-Saharan Africa.  
We performed a retrospective, case-control study of patients diagnosed with tuberculosis 
at a rural hospital in KwaZulu Natal, South Africa, where large numbers of MDR-TB and XDR-
TB cases have been identified.  All MDR-TB and XDR-TB patients who began treatment for TB 
between June 1, 2005 and August 31, 2006 and whose charts were available were included in the 
study.  A comparison group of patients without resistance to both isoniazid and rifampicin (non-
MDR-TB), matched 1:1 with the size of the MDR-TB and XDR-TB groups, was created.  
Clinical and laboratory data were obtained through review of hospital records, clinic registers, 
and the laboratory system.  We compared clinical characteristics to identify risk factors for MDR-
TB, XDR-TB, and mortality.  Bivariate and multivariate analyses were performed.
A total of 170 patients were enrolled in the study: 52 MDR-TB, 61 XDR-TB and 57 non-
MDR-TB.  Greater than 75% of patients from all groups were tested for HIV; HIV prevalence 
among those tested was 94% in the non-MDR group, 93% in the MDR group, and 100% in the 
XDR-TB group (P=1.000 for MDR versus non-MDR; p=0.089 for XDR versus non-MDR).  
Forty percent of MDR-TB patients and 57% of XDR-TB patients had no previous history of TB 
treatment, strongly suggesting transmitted drug resistance.  
Significant associations and risk factors for MDR-TB and XDR-TB in bivariate analysis 
included positive sputum smear (P=0.015, P=0.005), TB treatment in the past year (P<0.0001, 
P<0.001), and hospitalization in the past two years (P=0.007, P=0.004).  In multivariate logistic 
regression, positive sputum smear remained a significant risk factor for XDR-TB (adjusted odds 
ratio (AOR) 2.79, 1.20-6.47), and TB treatment in the past year remained a risk factor for both 
MDR-TB and XDR-TB (AOR 8.33, 95% CI 1.64-42.33; AOR 7.19, 95% CI 1.35-38.17).
Mortality for the non-MDR, MDR and XDR groups was 36.8%, 73.1% and 85.3%, 
respectively (P= 0.0001 for MDR versus non MDR; P<0.0001 for XDR versus non-MDR; 
P=0.109 for XDR versus MDR); median survival from TB diagnosis was 199 days, 103 days, and 
92 days, respectively (P<0.001).  In Cox Proportional Hazards model, positive sputum smear 
(P=0.003), MDR-TB (P=0.028), XDR-TB (P=0.002), and CD4 cell count less than 200 
cells/mm3 (P=0.037) were significant risk factors for mortality.
Forty of the 170 patients had sputum isolates with differing resistance patterns, and 18 
moved from a lower to a higher resistance category; this increasing drug resistance appeared to be 
more likely the result of super-infection than amplification.
A significant proportion of MDR-TB and all XDR-TB appear to be due to primary 
resistance, with nosocomial transmission playing a critical role.  MDR-TB and XDR-TB carry 
extraordinarily high mortality rates in this setting; previous hospitalization, previous TB 
treatment, positive sputum smear and low CD4 count may be used to target drug susceptibility 
testing for patients at high risk of drug resistant TB and mortality.
iii
ACKNOWLEDGEMENTS
I’d like to offer my sincere appreciation to a number of people who contributed to my work 
in Tugela Ferry and the generation of this manuscript.  First, I’d like to thank Dr. Tony Moll, 
who has worked tirelessly for the destitute ill of Msinga for nearly two decades and taught 
me much about medicine and service.  Before antiretrovirals were available in South Africa, 
Tony helped those with end-stage AIDS to die as peacefully as possible; now, he sees them 
through their recovery—providing food, housing, and a beautiful view as they undergo their 
Lazarus transformation.  Moreover, without Tony, XDR-TB may have slipped and 
marauded surreptitiously through KwaZulu Natal for several more years before it was 
recognized for the threat that it is.  I’m grateful for the assistance and endless hospitality of 
other staff at Church of Scotland Hospital and Philanjalo, including Eugene Meyer, Dr. 
Theo Van Der Merwe, Dr. Francois Ekstein, Smatoza Khoza, the Gogos, and the staff of 
the ARV clinic and TB DOTS office.  I thank Dr. Frank Bia, reviewer for this thesis, for his 
time, careful reading and helpful comments throughout the work.  Dr. Neel Gandhi’s 
contribution merits particular thanks; Neel patiently helped me from start to finish of this 
project—steering me from database creation through SAS analysis, reading countless drafts, 
and fine-tuning the discussion. Finally, I extend my gratitude to my advisor and mentor, Dr. 
Gerald Friedland.  “Prof” has made countless pioneering contributions to the understanding 
of HIV/AIDS and now to the field of drug-resistant tuberculosis.  But his academic laurels, 
though many, pale in comparison to his inspiring work as a great humanist physician.  
This research was supported by the James G. Hirsch Fellowship, the Office of Student 
Research, the Yale Center for Interdisciplinary Research on AIDS, and the Yale AIDS 
Program.
This work was for the patients at Church of Scotland Hospital, Tugela Ferry, South Africa.
How should they have given a thought to anything like plague, which rules out any future, cancels journeys, 
silences the exchange of views.  They fancied themselves free, and no one will ever be free so long as there are 
pestilences. – Albert Camus
iv
TABLE OF CONTENTS
ABSTRACT            ii
ACKNOWLEDGEMENTS            iv
COMMON ABBREVIATIONS             1
INTRODUCTION            3
   Tuberculosis and South Africa            
   Review of Tuberculosis Drug Resistance
   Emergence of Multidrug-Resistant Tuberculosis Worldwide
   Multidrug-Resistant Tuberculosis in South Africa          
   ‘The Tugela Ferry Outbreak’ of Extensively Drug Resistant Tuberculosis
   Clinical Issues in Drug Resistant Tuberculosis
METHODS          23
    Setting        
    Study Design        
    Selection of Subjects        
    Classification of Patients with Multiple Resistance Patterns         
    Data Collection         
    Mycobacterial Culture and Drug Susceptibility Testing Methods                                 
    Statistical Analysis         
    Ethics and Institutional Review            
RESULTS          33
    Demographics and Clinical Characteristics by Drug Resistance Group
    Mortality
    Drug Resistance Patterns Among Isolates
    Changes in Drug Resistance Patterns
TABLES          42
FIGURES          52
DISCUSSION          55
    Clinical Predictors of MDR-TB and XDR-TB
    Predictors of Mortality
    Observed Drug Resistance Patterns and Changes in Resistance
    Study Limitations
    Conclusion
REFERENCES          70
1
COMMON ABBREVIATIONS
COSH Church of Scotland Hospital
CPX Ciprofloxacin
DOTS Directly Observed Therapy Short-course
DST Drug Susceptibility Testing
EMB Ethambutol









XDR-TB Extensively Multidrug-Resistant Tuberculosis
2
INTRODUCTION
Tuberculosis and South Africa
Despite the availability of effective diagnostic, preventive, and curative 
technologies, tuberculosis (TB) remains the number one cause of adult deaths by a 
curable infectious disease worldwide (1).  In 2004, the last year for which global TB 
estimates are available, there were an estimated 9 million new cases and 14.6 million 
prevalent cases of tuberculosis, resulting in 3-4 million deaths (2).  Control of the disease 
has been highly uneven across various parts of the world.  While incidence has declined 
dramatically since the early 19th century in the industrialized world, worldwide incidence 
has been slowly increasing in recent years, largely as a result of dramatic rises in the 
former Soviet Union and Africa (2, 3).  
The developing world now bears 95% of all cases of TB, of which 70% occur on 
two continents: Asia and Africa.(2).  Countries of Sub-Saharan Africa have witnessed the 
worst trends in recent years.  Poor health infrastructure and a scarcity of human and 
financial resources have combined with soaring HIV rates to effect a dramatic rise in TB 
incidence in this region (4-6).  Eight of the top ten countries by TB incidence are in Sub-
Saharan Africa, and the average incidence among these countries is 4 times the global 
rate and 140 times that of the United States (2).  Mortality from tuberculosis is likewise 
disproportionately high in the developing world, in general, and in Sub-Saharan Africa,
in particular.  98% of all deaths from TB occur in developing countries.  Africa has the 
highest mortality rates and lowest treatment success rates of any region in the world (2).  
Within Africa, South Africa has the second highest TB incidence and the highest 
number of reported TB cases.  Approximately 339,000 cases of tuberculosis occur every 
3
year, resulting in an estimated 64,000 deaths (2).  Sixty percent of all incident cases occur 
in people infected with HIV.  As TB incidence and prevalence continue to rise, DOTS 
case detection rate has actually been falling in recent years, making evident the struggle 
that the public health infrastructure is facing in meeting the demands of the growing 
disease burden.  The DOTS treatment success rate was 67% nationwide in 2003, well 
below the WHO’s standard of 85% for DOTS programs, and in some areas is 
substantially lower.
Review of Tuberculosis Drug Resistance
Since the introduction of the first effective anti-TB drug, streptomycin, in the late
1940’s, resistance of Mycobacterium tuberculosis to chemotherapeutic agents has been 
understood as a major problem in the management of TB disease.  Clinical relapse after 
three to six months of improvement was observed in the earliest studies of streptomycin
(7, 8).  Randomized controlled trials carried out by British researchers upon the 
introduction of PAS in 1948 found that patients receiving combined therapy (PAS and 
SM) had lower rates of relapse than those receiving either drug alone (9, 10).  M.
tuberculosis has been able to acquire resistance to every effective chemotherapeutic agent
used against it.
Tuberculosis drug resistance can be either primary (transmission of resistant 
organisms) or secondary (resistance acquired in the host related to inadequate treatment).  
There are four broad categories of mechanisms of acquired resistance to drugs by M. 
tuberculosis: 1) the creation of a lipid-rich cell wall that can reduce the permeability of 
drugs (and arrest phagasome maturation); 2) the production of enzymes that degrade or 
modify compounds, rendering them useless; 3) the efflux of drugs through protein 
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pumps, described for isoniazid and ethambutol; and 4) spontaneous chromosomal 
mutations that affect key drug targets (11-14).  Among these, the fourth mechanism is 
considered to be the most important. Mobile or horizontal transmission of resistance, 
such as plasmid mediated resistance, does not occur in M. tuberculosis.  Random genetic 
mutations occur with low but predictable frequencies in the range of one mutation per 106
to 109 organisms. The frequency of mutations conferring resistance to particular agents 
varies from the range of 10-3 for many second line drugs (thiacetazone, ethionamide, 
capreomycin, cycloserine, and viomycin) to an intermediate level (around 10-6) for some 
first and second line drugs (isoniazid, streptomycin, ethambutol,  kanamycin, and p-
amino salicylic acid) to the lowest levels for rifampicin, on the order of 10-8 to 10-10.  
When large populations of M. tuberculosis are formed in a host and selective pressure is 
placed by a chemotherapeutic agent, the small population of M. tuberculosis that has 
evolved resistance to the agent will continue to multiply while the susceptible M.
tuberculosis is suppressed.  This enables the drug resistant organism to become the 
dominant organism in the host.
In order to prevent this scenario from occurring, the central strategies in therapy 
are to: 1) administer several chemotherapeutic agents, such that if there are organisms 
resistant to one or two agents, they will be killed by the other agents; 2) provide therapy 
for an adequate duration in order to ensure eradication of populations of M. tuberculosis,
which evades both host immune response and drug actions by a number of intricate 
cellular mechanisms (14).  Because the probability of two simultaneous mutations—the 
product of the individual probabilities of mutations—is small (10-11 to 10-14) compared 
with typical bacillary loads (up to 109 in a pulmonary cavity), the sustained presence of 
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two or more effective drugs should eradicate the entire population of bacilli (this 
traditional model, while useful, is an oversimplification due to the formation of 
microenvironments with differing drug concentrations and activities) (14).  The time 
period of acquired resistance under monotherapy varies between agents and has been well 
characterized for many of the initial anti-TB agents; in a 1952 study of isoniazid 
monotherapy, 11%, 52% and 71% of patients developed resistant strains after one, two 
and three months, respectively (15).
Not surprisingly, the most common ways in which M. tuberculosis drug resistance 
evolves or amplifies in the host involve the violation of these principles.  The causes of
these violations range widely, from the actions of the individuals, by nonadherence, to 
those of the health provider, by improper regimen selection or suboptimal dosing, to the 
failure of TB control programs to provide a consistent supply of necessary agents (11).  
Understanding of these causes has evolved considerably over the past two decades, 
trending towards increasing recognition of the impact of the social, economic and 
political environments in which therapy takes place upon the likelihood that patients will 
be exposed to the proper treatment for an adequate duration (16, 17).
Numerous host factors have been implicated in the facilitation of acquired drug 
resistance, including the development of local tissue microenvironments recalcitrant to 
antibiotic penetration or activity and the failure of the immune system to act in synergy 
with antibiotic activity (14).  Compromise of the host immune response, such as that 
caused by infection with HIV, may be a significant risk factor for the evolution of drug 
resistance.  This is discussed in more detail below.
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More recently, the use of chemotherapeutic agents with efficacy against 
tuberculosis for treatment and prophylaxis of other diseases has been implicated in the 
development of resistance to these drugs by M. tuberculosis.  This includes empiric use 
of quinolones for community acquired pneumonia, when in fact the patient is manifesting 
tuberculosis, or aminoglycosides for a number of diseases (18-20); both are important 
second line tuberculosis classes that are widely used in routine clinical practice for the 
treatment of other diseases..  The duration of exposure required for resistance to evolve 
has not been well characterized yet; nevertheless, this has led some high TB-prevalence 
countries to regulate empiric use of these classes of drugs.  The use of rifamycins in the 
prophylaxis of mycobacterium avium-intracellulare disease has been associated with the 
development of rifampicin-resistant TB in HIV patients (21, 22).
Finally, there exists considerable cross-resistance and class-resistance to 
antituberculosis agents.  All rifamycins have high levels of cross resistance (23, 24).  
Fluoroquinolones have considerable cross resistance, but in vitro data suggests that newly 
introduced fluoroquinolones may be effective when resistance to previous generation 
fluoroquinolones is present (cross resistance within earlier quinolones, such as 
ciprofloxacin and ofloxacin, is very high) (23, 24).  Kanamycin and amikacin have 
almost 100% cross resistance (23, 24).  Streptomycin is believed to have low levels of 
cross resistance with kanamycin and amikacin (23, 25).
Emergence of Multidrug Resistant Tuberculosis
Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at least 
isoniazid and rifampicin (the two most important first-line drugs), appeared after the 
introduction of rifampicin in 1966.  Unit 1990, however, most MDR cases occurred in 
7
patients receiving prolonged, inappropriate therapy; while sporadic outbreaks of primary 
transmission occurred, the magnitude and impact was relatively limited (26).  In the early 
1990’s, several large outbreaks of MDR-TB unfolded in hospitals and institutions in the 
United States, announcing MDR-TB as a major public health threat (27-30). In New 
York City, where the largest number of MDR-TB cases were reported, as many as one in 
five TB cases involved MDR (28).  Strong evidence of recent, primary transmission of 
resistant TB was established.  Among patients who had never been treated before, 23% 
were resistant to one or more drugs (28).  Molecular fingerprinting by restriction 
fragment length polymorphism (RFLP) implicated a single strain in 22% of MDR cases 
in New York City in 1992 (31).  High rates of nosocomial transmission, to health care 
workers and HIV positive patients in particular, were documented (27, 29).  Together, 
these circumstances demonstrated the rapidity with which MDR-TB could spread through 
susceptible populations.  Through a massive investment of human and financial resources
(estimated by some to be as high as a billion dollars), the MDR-TB epidemics in New 
York and elsewhere in the country were brought under control and the incidence of 
MDR-TB plummeted (32). Subsequent nosocomial and institutional outbreaks in Italy, 
Spain, Russia and Chile made it clear that MDR-TB ranked among the most serious 
public health issues facing the world (33-36).  
Global data on the prevalence of MDR-TB, however, were lacking.  The first
global survey of TB drug resistance was published in 1997 by the Global Project on Anti-
TB Drug Resistance, a collaboration between the World Health Organization and the 
International Union Against Tuberculosis and Lung Disease.  Two subsequent global 
surveys, covering the periods of 1996 to 1999 and 1999 to 2002, further elucidated the 
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worldwide picture of drug resistance (37).  The most recent data published by the Global 
Project revealed that virtually all countries surveyed reported TB drug resistance and 
estimated that 424,000 cases of MDR-TB emerged in 2004 (38).  With the exception of 
Botswana, which was found to have rising rates of MDR-TB, no trend data was available 
from Africa, a result of the poor laboratory infrastructure and surveillance on the 
continent.  Twenty sites worldwide reported drug resistant TB prevalence in excess of 
20%, and eleven sites reported rates of MDR-TB among new cases of over 6.5%.  The 
geographic distribution of MDR-TB is highly uneven and ranges from 0.7% in new cases 
in established market economies, to around 2% in Africa, Southeast Asia and South 
America, and over 10% in some areas of the former Soviet Union and several provinces 
in China.  Among previously treated cases, the rate of MDR is often several fold higher; 
by 2002, nine settings had been identified as having MDR rates of above 30% in 
previously treated cases.
More recently, the emergence of extensively drug resistant tuberculosis (XDR-
TB), defined as TB resistant to isoniazid, rifampicin, quinolones and at least one of three 
injectable second line drugs (kanamycin, capreomycin, or amikacin), in every region of 
the world has raised further alarms about the future of TB control (see “The ‘Tugela 
Ferry Outbreak’ of Extensively Drug Resistant Tuberculosis,” below) (39-41).  A review 
of global DST data conducted by researchers at the CDC found 347 isolates of XDR-TB 
worldwide, accounting for 2% of all TB isolates surveyed and 15% of MDR-TB isolates; 
data from African and Asian countries, other than South Korea, were notably lacking
(39).  In early 2005, the first reports emerged of an outbreak of XDR-TB at a hospital in 
rural KwaZulu Natal, South Africa, confirming fears about the rise of drug resistant TB 
9
in high HIV prevalence settings (see “The ‘Tugela Ferry Outbreak’ of Extensively Drug
Resistant Tuberculosis,” below) (41).  
There is tremendous concern among public health practitioners that the rise of 
drug resistant tuberculosis will undermine the success of extent TB DOTS programs and 
worldwide TB control.  The ability of DOTS programs to reduce transmission and 
incidence of both drug susceptible and drug-resistant tuberculosis is debatable; while 
some studies have shown successful reduction of drug resistance under the WHO strategy
(42), others have demonstrated an “amplifier effect” of increasing drug resistance under 
DOTS-prescribed short-course chemotherapy (43-46).  One study of patients receiving 
short course chemotherapy in a penitentiary hospital in Siberia found that over 3% of 
patients completing treatment, and over twenty percent of patients who began treatment 
with an isolate resistant to three first-line drugs, had amplified resistance over the course 
of therapy (47). Large scale epidemiological data is presently lacking, but mathematical 
models have suggested that MDR-TB hotspots could evolve in areas with successful 
DOTS programs due to the amplifier effect (48).
Treatment of multidrug-resistant tuberculosis with second line drugs is much 
more expensive and requires a longer duration of therapy.  As such, it became a 
contentious public health issue in the past decade, pitting moral and cost-effectiveness 
arguments against each other in debates about global health resource allocation (49).  
Prior to 1999, the prices of second line drugs were exorbitantly high and no global 
mechanism existed for coordinating supply,  negotiating drug prices, financing programs, 
setting treatment guidelines and standards, and overseeing program performance (50).  In 
1999, the WHO and its partners launched a “DOTS-Plus for MDR-TB” initiative,
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followed by the “Green Light Committee” (GLC) a year later (51).  Together, these
bodies have increased access to second line drugs in resource poor settings and ensured 
that treatment of MDR-TB supplements, rather than detracts from, the success and 
resources of existing TB DOTS programs.  Despite the success that the DOTS Plus 
initiative and GLC have had in scaling up MDR-TB treatment in resource poor countries, 
only 10,000 patients, or less than 5% of the world’s total cases, are currently receiving 
second line drugs (SLD) through this mechanism (24).  The overwhelming majority of 
patients afflicted with MDR-TB in developing countries remain without access to second 
line drugs.
Multidrug-Resistant Tuberculosis in South Africa
Tuberculosis drug resistance surveillance throughout Africa has been extremely 
relatively limited due to poor public health infrastructure and the paucity of laboratories 
with capacity to perform drug susceptibility testing (DST); nevertheless, the existing data 
suggest that African countries have some of the lowest rates of multidrug-resistant 
tuberculosis of developing countries. Reasons for this include the relatively recent 
introduction of rifampicin into the public sector and delays in drug resistance surveillance
and reporting amidst volatile HIV and TB epidemics (52).
Compared with most Sub-Saharan African countries, South Africa has an 
advanced public health infrastructure and far greater capacity for drug resistance 
surveillance.  Between 1965 and 1991, twenty-five annual surveys of drug resistance 
were carried out by the Tuberculosis Research Institute of the South African Medical 
Research Council (53).  The results of these surveys found a dramatic decline in 
prevalence of both primary and acquired drug resistant tuberculosis.  In 1995, the 
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Medical Research Council’s TB research programme was suspended due to budgetary 
constraints.  Several smaller drug resistance surveys, including two provincial surveys, 
were undertaken, but national data were not collected again until 2001.  The data from 
these interim surveys suggested that the prevalence of MDR-TB remained low in the 
mid-1990s but began to rise in the latter half of the decade (50, 54-57).
The most recent national estimates of tuberculosis drug resistance in South Africa 
were based upon a survey covering nine provinces of the country and carried out between 
2001 and 2002 by the Tuberculosis Lead Programme of the Medical Research Council in 
South Africa, which is part of the Global Network of Supranational Reference 
Laboratories for Drug Resistance Surveillance of the World Health Organization (58).  
Nationwide, any drug resistance was detected in 7.8% of isolates from new patients and 
15.5% of isolate from retreatment cases.  MDR prevalence was 1.6% among new cases 
and 6.6% among retreatment cases.  A quarter of all MDR cases had resistance to all four 
first line drugs against which they were tested (isoniazid, rifampicin, ethambutol, and 
streptomycin).  In KwaZulu Natal (KZN), the prevalence of MDR-TB among new 
patients and retreatment patients were marginally higher than the national average at 
1.7% and 7.7%, respectively.  The prevalence of HIV among pan-susceptible, any 
resistance and MDR patients were 63.2%, 76.1% and 76.9%.  The survey in KZN
suffered from the failure of most districts to submit an adequate number of specimens; 
only two of the eight districts met the sample number targets, and five of the eight 
districts reported less than 70% of the targeted number of specimens.  DST for second
line drugs was not performed in this survey.
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Though the rates of MDR-TB among new and previously treated cases were 
relatively low compared with some areas of Eastern Europe, Central Asia and Russia, the 
absolute number of TB patients in South Africa is so high that the burden of MDR-TB is
enormous.  In KZN alone, the estimated number of new MDR cases per year, by these 
rates, was 1385 to 2616—ten to twenty times the total number of cases of MDR-TB in 
the entire United States in 2005 (58, 59).  The declining case identification and treatment 
success rates in South Africa in recent years make the rise of drug resistant tuberculosis a 
likely and concerning possibility (2).  A recent survey of drug resistance at one hospital 
in KZN found an MDR-TB rate of 39% among sputum culture positive cases (41).  
Notably, the district in which this hospital lies was not included in the drug resistance 
surveillance study of 2000-2002, suggesting that the survey may have failed to identify 
significant MDR hotspots.
‘The Tugela Ferry Outbreak’ of Extensively Drug Resistant Tuberculosis
In early 2005, researchers from a joint U.S.-South African team conducting a 
prospective trial of HIV and TB treatment integration at a rural hospital in Tugela Ferry,
KwaZulu Natal, South Africa, noted higher than anticipated rates of mortality in their 
cohort of subjects receiving antiretroviral therapy concomitant with antituberculosis 
therapy (41).  Further investigation revealed that six of the 119 patients co-infected with 
HIV and TB were infected with M. tuberculosis that was resistant to all six drugs against 
which it was tested: isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and 
kanamycin.  Increased surveillance undertaken as a result of these findings revealed that 
between the period of January 2005 and March 2006, 53 patients presenting to the 
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hospital were infected with organisms showing this same pattern of resistance to six 
drugs, meeting the WHO’s new criteria for XDR-TB (60).  Mortality was exceptionally 
high (98%), with the median survival from the time of sputum collection being just 16 
days.  All patients for whom HIV status was known (83%) were positive.  The majority 
(55%) of patients had never received previous treatment for tuberculosis and only 15% 
had failed or defaulted therapy.  Genotyping of 46 of the isolates revealed that 39 (85%) 
were genetically similar.  These findings, taken together, were considered evidence of 
primary drug resistance with recent transmission, and the high proportion of patients who 
were hospitalized in the past year was suggestive of nosocomial transmission.  Further 
concerning was the high prevalence of MDR-TB (39%) among culture positive cases, a 
figure far higher than that found by a province-wide tuberculosis resistance survey 
undertaken three years prior (58).
The results of this investigation, presented in August of 2006 at the International 
AIDS Conference, provoked alarm in the public health community.  The findings in 
Tugela Ferry represented one of the first instances of the recognition of large number of 
cases of highly drug resistant tuberculosis in a high HIV-prevalence setting; additional 
laboratory data from the provincial diagnostic mycobacteriology laboratory revealed that 
XDR-TB isolates had been found in 28 hospitals across the province. The World Health 
Organization, in collaboration with the South African Medical Research Council and U.S. 
Centers for Disease Control, responded by convening an expert consultation on XDR-TB 
in Johannesburg in September, followed by the first meeting of the Global Task Force on 
XDR-TB in Geneva in October, 2006 (61).  The WHO Global Task Force on XDR-TB 
revised the definition of XDR-TB and promulgated recommendations for its prevention 
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and control (62).  According to the revised definition of XDR-TB, the total number of 
XDR cases identified at this single hospital between January 2005 and December 2006 
was over 200.
Clinical Issues in Drug Resistant Tuberculosis
Laboratory and Clinical Diagnosis
Drug susceptibility testing (DST) is the principal strategy for establishing the 
resistance pattern of tuberculosis to antituberculosis chemotherapeutic agents.  The 
classic approach to DST involves inoculation of a solid media (e.g. Lowenstein-Jensen, 
7H10 or 7H11 agar) impregnated with a tuberculosis drug in a defined concentration with 
either a concentrated specimen (direct method) or pure culture (indirect method) and then 
assessing growth by one of several methods: the proportions method, the absolute-
concentration method, or the resistance-ratio method (63).  According to the proportions 
method, a resistant isolate is one in which the number of colonies growing on the drug-
impregnated plate is greater than or equal to 1% of the number of colonies on a non-drug 
impregnated plate (direct comparison between plates for colonies can be made by 
increasing the concentration of the isolate on the impregnated plate by 100 fold).
Additional methods include the BACTEC-460, an automated liquid medium 
system that assesses mycobacterial growth by detecting the consumption of radioactive 
(14C) mycolic acids through measuring the release of 14CO2 (63).  More recently, a 
nonradioactive automated BACTEC-960 system has shown promise as an alternative for 
mycobacterial culture and DST in advanced laboratories.  These systems are more rapid 
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but are expensive and require a laboratory infrastructure far beyond that available in 
many resource poor settings.
Molecular approaches for identifying drug resistant M. tuberculosis, including 
rapid genetic tests, are currently in use in many laboratories and are gaining interest for 
their speed and potential for use in areas with limited laboratory capability.  The most 
commonly used tests assay for the rpoB gene associated with rifampicin resistance (11).  
Several large studies are currently underway to evaluate the use of rapid rifampicin tests 
in resource-limited settings.  Finally, the recent demonstration of a rapid, low cost 
technique for culture and susceptibility known as “Microscopic Observation of Drug 
Susceptibility” (MODS) has generated considerable excitement about the potential for 
cheap and rapid culture and DST, particularly in resource limited settings.  In 
demonstration and operational studies in Peru, MODS was shown to be highly sensitive 
and specific, cost a fraction of existing culture and DST methods, and provide results in 
half the time of BACTEC and less than a fifth the time of conventional Lowenstein-
Jensen agar with the proportion method (64).  However, the sensitivity and specificity of 
this method for identifying resistance to SLDs has not been studied, and biosafety 
concerns still present a major obstacle to the rapid introduction of this test into resource 
limited environments.
Criteria for drug resistance testing for most SLDs (excluding more recently 
introduced drugs, such as quinolones) were established nearly 50 years ago; nevertheless, 
their validity in terms of correlation with in vivo outcomes has recently come into
question (65).  DST for SLD is considered to be more complicated, in part because 
critical drug concentrations defining resistance are not as close to the minimal inhibitory 
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concentrations for SLDs as they are for first-line drugs (66).  Furthermore, proficiency 
metrics, such as those obtained for first-line drug susceptibility testing, are unavailable 
for most SLDs (though proficiency testing exercises among supranational reference 
laboratories is underway).
In the vast majority of clinical settings in the developing world, where most cases 
of tuberculosis occur, DST for first or second line drugs is not routinely performed.  Even 
in areas where DST is available, routine use in all newly diagnosed patients is often 
infeasible due to costs or the limited sample processing capacity of laboratories. Further, 
the existing methodologies require 2-3 months for diagnosis. As such, the clinical history 
plays a large part in diagnosing probable drug resistance and targeting DST.  Risk factors 
for drug resistant tuberculosis include: failure of short-course chemotherapy (SCC), 
known exposure to an MDR-TB case, known exposure to a patient who died while taking 
SCC, relapse after default, non-adherence to SCC, co-morbid conditions associated with 
malabsorption, and residence in areas (or institutions) of high MDR-TB prevalence (11).  
The role of outcomes from previous TB treatment in predicting drug resistant TB is
significant yet not fully characterized; the prevalence of TB and of drug resistant TB in 
the population, as well as the immune status of the patient, probably impact considerably 
the predictive value of this factor.  In several case control studies assessing risk factors 
for drug resistant tuberculosis, the increased risk associated with previous TB treatment 
ranges from two fold to more than ten fold (67-74).  However, little data from Africa or 
high HIV prevalence settings is available.
In patients who are receiving therapy, those who remain or become sputum 
positive at 4 months, have persistent fevers, or have worsening clinical or radiological 
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parameters should provoke a high suspicion for drug resistance.  To date, however, there 
are no reliable clinical algorithms for accurately predicting drug resistant tuberculosis
(52).
Fitness and Transmissibility
The debate surrounding the relative virulence or fitness of drug resistant strains 
compared with drug sensitive strains is an unresolved one.  Early animal models 
suggested that the development of drug resistance may be associated with a loss of 
virulence factors, such as catalase activity, by bacilli (75, 76).  Subsequent 
epidemiological studies, looking at cluster development of drug resistant versus drug 
susceptible cases and the differential development of secondary cases among contacts, 
affirmed this hypothesis by showing lower infection rates among groups exposed to drug 
resistant TB (77, 78).  However, other studies, including those of the “strain W” 
responsible for much of the New York City outbreak in the 1990s, have found drug 
resistant TB to be at least as virulent and transmissible (79, 80); “strain W”, in particular, 
was shown to be catalase positive.  In all likelihood, there is heterogenecity in virulence 
among strains of drug resistant TB.
Whether or not drug resistant tuberculosis is less fit or transmissible, cases of 
MDR-TB are likely to generate more secondary cases due to the prolonged infectious 
period associated with delayed identification, inadequate treatment, longer time to culture 
conversion once on SLD, and lower cure rates.  Moreover, mathematical models suggest 
that, even where strains of MDR-TB are less fit than pan-susceptible strains, hot zones of 
MDR-TB can develop, largely as a result of low cure rates and amplification probabilities
(48).
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HIV and TB Drug Resistance 
The associations between HIV infection and the development of multi-drug 
resistant tuberculosis have not yet been fully clarified. Among the most important 
unresolved questions is whether HIV infection is an independent risk factor for the 
development of multi-drug resistant tuberculosis.  Several studies have shown increased 
rates of drug resistant TB among HIV infected individuals (81-83), while other data, 
including the results of the Global Anti-TB Drug Resistance surveys, have failed to 
confirm this finding (37, 56, 84-86). Higher rates of drug resistant TB found in the 
smaller studies could, in part, be due to the fact that recently circulating strains are more 
likely to be drug resistant, and HIV-infected patients manifest TB disease more rapidly, 
such that they are disproportionately represented in the early stages of outbreaks of drug 
resistant TB.
While the population-level impact of HIV on drug resistance remains to be 
established, several clinical observations have been studied concerning the relationship 
between HIV disease and the development of drug resistance.  Patients with HIV have 
been observed to have higher rates of rifampicin monoresistance, further associated with 
diarrhea, prior rifabutin use (e.g. for MAI treatment/prophylaxis), positive AFB smear, 
nonadherence to therapy, severe immunosuppression, and antifungal therapy (22, 87).  
Patients co-infected with HIV have varying degrees of intestinal absorption of TB drugs
(88-90) and of treatment failure with standard regimens (91-93) both potentially 
increasing the risk of acquiring or amplifying TB drug resistance.  
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In addition to its role as a determinant or co-determinant of drug resistance, HIV 
disease and its management have clinical implications for the diagnosis and treatment of 
MDR-TB.  HIV-infected individuals undergoing treatment for MDR-TB have lower rates 
of treatment success and higher mortality than uninfected patients (94, 95).  Diagnosis of 
any form of TB, including MDR-TB, is more challenging in the presence of HIV disease, 
in that sputum smear and radiographic findings are less sensitive and extrapulmonary 
disease is more common than in uninfected patients (96-102).  Certain second line drugs 
are more toxic in patients infected with HIV, while the use of antiretrovirals 
concomitantly with SLDs may result in problematic drug-drug interactions (11, 24).
Finally, regardless of whether HIV is an independent risk factor for the 
development of MDR-TB at the individual level, the increased pool of susceptible 
patients who serve as both hosts and vectors for all forms of TB, including MDR-TB, is 
certain to increase the absolute burden of MDR-TB at a population level.  Moreover, at a 
programmatic level, the HIV epidemic, particularly in Africa, has overwhelmed and 
disrupted the established TB control programs, causing rising treatment failure rates and 
increasing the opportunity for drug resistant TB to emerge and spread.
Treatment of MDR-TB
Compared with therapy for drug susceptible tuberculosis, treatment of MDR-TB
requires a longer duration, is considerably more complicated, expensive, and toxic, and 
treatment success rates are typically lower.  Various treatment strategies have been 
employed, including the use of standardized treatment regimens based upon 
representative local susceptibility patterns, empirical treatment based upon previous 
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treatment history and local DST patterns, and individualized treatment designed on the
basis of individual DST results (24).  It is recommended that regimens include at least 
four drugs that are certain, or expected, to be effective and that the duration be a 
minimum of 18 months beyond sputum conversion.  Injectable agents should be used for 
a minimum of 6 months.  
Management of patients receiving second line drugs requires fairly intensive 
monitoring for drug toxicities and treatment failure.  While some cohorts have found high 
rates of treatment interruption due to side effects and toxicities, well designed programs 
have demonstrated that, in spite of the high frequency of adverse effects, life-threatening 
adverse events are uncommon and management in resource limited settings can be done 
successfully (103-105). Sputum culture conversion typically occurs between one to two 
months after the initiation of therapy, while smear conversion may take longer as it does 
not distinguish between viable and nonviable organisms (106).  Patients who have 
persistently positive sputum smears or cultures after three months of therapy with SLD 
should raise concerns for either poor adherence or improper regimen choice, and further 
evaluation including DST may be indicated (11).
Treatment outcomes among MDR-TB cases have varied widely; a recent survey 
of five GLC-approved sites in resource-limited countries found treatment success rates of 
70% (107).  A number of factors have been associated with treatment failure and death.  
In the aforementioned survey of GLC-approved sites in resource-limited countries, 
treatment success and death rates were 77% and 3.5%, respectively, in new cases and 
68.5% and 14% in previously treated cases.  Patients infected with HIV have consistently 
been found to have higher rates of mortality during MDR-TB treatment than HIV 
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uninfected individuals (94, 108).  One case series in South Africa found MDR-TB 
treatment success rates of 38% in HIV infected individuals, compared with 47% in those 
who were uninfected (109).  In another cohort in Peru, low baseline hematocrit and body 
mass index were each independently associated with decreased time to death, while the 
inclusion of pyrazinamide and ethambutol in the regimen (in patients with DST-
documented susceptible organisms) was independently associated with favorable 
treatment outcomes (106).  A review of MDR-TB treatment outcomes in Latvia found 
treatment success of 76% among HIV uninfected patients and of 56% among infected 
patients; resistance to ofloxacin was independently associated with a much slower time to 
culture conversion and an increased risk of poor outcomes (110).
At a programmatic level, the World Health Organization recommends that 
treatment of multidrug-resistant tuberculosis be based upon principles closely related to 
those of its general DOTS strategy for TB control: sustained political commitment; a 
rational case-finding strategy including accurate, timely diagnosis through quality-
assured culture and DST; appropriate treatment strategies that use second-line drugs 
under proper case management conditions; uninterrupted supply of quality-assured 
antituberculosis drugs; standardized recording and reporting system (24).  While these 
components can be expensive and require substantial investment of human and laboratory 
resources, the experience from multiple countries is that addressing drug resistant 
tuberculosis strengthens, rather than detracts from, national tuberculosis programmes.  
Moreover, data from Peru suggests that treatment of MDR-TB is cost-effective (111).  To 
date, however, DOTS Plus for MDR has not been implemented on a large scale in Africa, 
and data on outcomes from the region are limited.
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Need for Rapid Identification of MDR and XDR-TB Patients
The timely identification of patients with MDR-TB and XDR-TB is challenging 
and yet has significant implications on the outcomes for individual patients and their 
potential for spread to others.  Among the first 53 patient reported with XDR-TB in 
Tugela Ferry, the median survival from the time of sputum collection was 16 days; 
however, the results of sputum culture and DST by conventional methods (as are 
available KwaZulu-Natal) typically takes three to six weeks, meaning most patients had 
died before their diagnosis of XDR-TB was made.  Moreover, many patients are 
hospitalized while awaiting sputum culture and DST results; in Tugela Ferry, patients 
with unknown TB resistance patterns share a single, large room with approximately 40 
other patients.  Such circumstances make nosocomial transmission of drug resistant 
tuberculosis highly probable.
While the introduction of rapid culture and DST techniques is needed in this 
setting, the requisite infrastructure and resources are not yet available.  As such, there is 
an urgent need for the further elucidation of the clinical characteristics of MDR-TB and 
XDR-TB patients and the identification of clinical predictors of drug resistant TB.  Such 
information may facilitate the early identification of patients with MDR-TB and XDR-
TB, hopefully leading to improved treatment outcomes and reducing community and 
nosocomial transmission.  In settings without access or with limited access to DST, 
which include most of the developing world, clinical assessment of TB for drug 
resistance is the primary tool for diagnosis, making the development of clinical predictors 




This study was carried out at the Church of Scotland Hospital (COSH), a 360 bed 
provincial government district hospital in the Msinga subdistrict of KwaZulu Natal, 
South Africa, a rural region of approximately 2000 km2.  COSH provides medical 
services to a catchment population of approximately 250,000 Zulu people, living in 
traditional family compounds dispersed widely through areas with few roads, poor 
transportation infrastructure, sparse electricity and a dearth of potable water.  
Unemployment rates are estimated to be in excess of 60%. The prevalence of HIV 
infection among inpatients and women presenting to the maternity ward are 40% and 
20%, respectively.  There are ten full-time physicians working at the hospital at any given 
time, and laboratory infrastructure exists for sputum microscopy for acid-fast bacilli but 
no culture or other microbiological tests.
At present, there are four TB wards: two general TB wards (one male, one 
female), each containing approximately 35 beds; and two TB “isolation” wards (one 
male, one female), each containing 10 beds.  The male isolation ward is a separate 
building, whereas the female isolation ward is a partitioned room of the female TB ward 
that has no door and an open airflow with the general female TB ward.  Both wards are 
almost always over capacity, forcing a number of patients to sleep on the floor. In 
addition there is one male and one female internal medicine ward, a surgical ward, 
pediatrics ward, and obstetrics wards. HIV testing us offered to all patients with TB, and 
around 70% of patients accept testing. 
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COSH has been a site for a government-sponsored TB DOTS program since 
1993.  Diagnosis is made by sputum microscopy, x-ray, and/or clinical criteria, according 
to the South African National Tuberculosis Guidelines (112). Each year, approximately 
1800 cases of tuberculosis are diagnosed and managed by COSH and its surrounding 
satellite clinics.  All patients receive free directly observed therapy, administered at home 
by community health workers or in nearby clinics.  A standard regimen is used, 
consisting of isoniazid, rifampicin, ethambutol and pyrazinamide for a two month 
intensive phase, followed by a 4-month continuation phase with isoniazid and rifampicin.  
These are given as fixed dose combination pills containing 4 drugs (intensive phase) or 2 
drugs (continuation phase), reducing pill burden.  Since June 2005, sputum samples for 
all patients with signs and symptoms of tuberculosis have been collected and sent for 
culture and drug susceptibility testing at the provincial diagnostic mycobacteriology 
laboratory in Durban.  Results are transmitted back to COSH via paper copies once 
weekly and are also available to COSH staff on an intranet-based laboratory reporting 
system.  The details of the culturing and drug susceptibility testing methods are described 
in the “Mycobacterial Culture and Drug Susceptibility Testing Methods” section.
Study Design
This was a retrospective, case-control control study of patients diagnosed with 
tuberculosis at a rural hospital in KwaZulu Natal, South Africa.  This site was chosen due 
to the recognition of an outbreak of XDR-TB in 2005 (see INTRODUCTION).  The primary 
objective of the study was to identify clinical predictors of tuberculosis drug resistance 
and mortality among this population.  The study was designed as a case-control study 
comparing three groups of patients: patients with XDR-TB, patients with MDR-TB but 
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not XDR-TB, and patients with non-MDR-TB.  Cases were defined according to drug 
susceptibility testing of sputum cultures, described below.  XDR-TB was defined as 
resistance to at least isoniazid, rifampicin, ciprofloxacin and kanamycin.  Ciprofloxacin 
and Kanamycin were the only second line drugs against which M. tuberculosis is 
currently tested at the referral laboratory for COSH, the provincial diagnostic 
mycobacteriology laboratory at the Inkosi Albert Lathuli Central Hospital (See 
Mycobacterial Culture and Drug Susceptibility Testing Methods below).  MDR-TB 
was defined as resistance to at least isoniazid and rifampicin.  Non-MDR-TB was defined 
as susceptibility to either rifampin or isoniazid or both (irrespective of susceptibility to 
other drugs).  While XDR-TB is a subgroup of the category of MDR-TB (all XDR
isolates must have resistance to isoniazid and rifampicin), the MDR-TB group in this 
paper refers to patients who had only MDR-TB and did not meet the criteria for XDR-
TB.
The study period was from June 1, 2005 through August 31, 2006.  The starting 
point of this period was selected because from this point forward, the hospital adopted a 
policy whereby sputum samples for culture and drug susceptibility testing were collected 
for all patients suspected of having tuberculosis.  This reduced bias in patients having 
sputum cultures, in that, rather than targeting patients suspected of failing treatment for 
DST, clinicians sought to acquire DST for all patients.
The primary outcomes of interest were risk factors for MDR-TB and XDR-TB.  
Secondary outcomes were risk factors for death.  Variables or factors examined included 
demography, treatment outcomes, mortality, HIV status, number and duration and timing 
of hospitalizations prior to and subsequent to treatment, time elapsed between initiation 
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of treatment and death, time elapsed between treatment initiation and DST, time elapsed 
between DST and death, use of second line drugs, recorded symptoms, weight changes, 
use of antiretroviral therapy, CD4 count, laboratory results (hemoglobin and ESR) at 
diagnosis and on therapy, and sputum smear and culture results.
Selection of Subjects
Selection of subjects for inclusion in the study was carried out in the following 
way. First, a list of patients with MDR and XDR-TB was compiled based upon a registry 
kept and maintained by the staff at COSH.  Charts were obtained from the hospital’s TB 
DOTS office and the hospital’s central file storage room.  All patients diagnosed by 
sputum drug susceptibility testing as having MDR or XDR-TB between the period of 
June 1, 2005 and August 31, 2006 for whom charts could be located were included.  
Patients who were diagnosed with TB before June 1, 2005 were excluded because prior 
to this date, sputum for culture and DST were only targeted at patients with treatment 
failure.  Since June 1, 2005, the hospital policy has been to obtain sputum for culture and 
DST on all newly diagnosed TB patients.
Once review of charts was completed, patients whose current episode of TB was 
diagnosed and treatment initiated before June 1, 2005 were excluded from the study. 
These were patients who began treatment prior to June 1, 2005 but whose diagnostic 
sputum culture was collected after June 1, 2005. This excluded 13 patients with XDR-
TB and 10 patients with MDR-TB, leaving 52 patients in the MDR-TB group and 61 
patients in the XDR-TB group.
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 The control group of non-MDR patients was compiled by reviewing the TB 
DOTS registry, which contains all patients diagnosed with tuberculosis at COSH, and by 
cross-checking with the Kwazulu-Natal Department of Health laboratory server.  All 
patients diagnosed with TB at COSH after June 1, 2005 were eligible for inclusion.  The 
first 60 patients with a positive sputum culture, a non-MDR-TB first resistance pattern, 
and an available medical chart were entered into the study. Three patients were later 
excluded due to the absence of chart information, leaving 57 patients in the non-MDR-
TB group.
Classification of Patients with Multiple Resistance Patterns
Many patients had two or more M. tuberculosis isolates with different drug 
susceptibility patterns, some of which fell in two or more different drug resistance 
groups.  For comparative purposes, it was necessary to group patients according to drug 
susceptibility pattern, but to do so in a cross-sectional manner, without assigning patients 
to multiple groups.  This presented a challenge in categorizing these patients into drug 
resistance groups without biasing the groups.  For example, if the highest level of 
resistance was used to classify patients, then all patients who had a pan-susceptible 
sputum first and then developed MDR-TB or XDR-TB would be classified in the latter 
two groups; when analyzing the outcomes of the pan-susceptible group, it would appear 
as though no patients went on to develop MDR-TB or XDR-TB.  If the first sample found 
in the time period under examination was used to classify patients, no patients with 
MDR-TB or XDR-TB could have a prior non-MDR-TB sample, which would obscure 
acquired and transmitted resistance.
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To address this problem and minimize biases in clinical predictors and outcomes, 
patients who had two or more M. tuberculosis isolates with different drug susceptibility 
patterns were treated in the following manner during subject selection.
For all groups, if the differing isolates were collected within three days of one 
another, the patient was grouped according to the highest level of drug resistance.  For 
example, if sputum samples from one day showed an isolate with pan-susceptible 
tuberculosis and another isolate within 3 days had XDR-TB, the patient was placed in the 
XDR-TB group.  
For the creation of the MDR and XDR groups, if the isolates with differing DST 
patterns were collected on separate days more than 3 days apart, the patient was grouped 
according to the highest level of resistance found.
The creation of the non-MDR-TB group was done systematically through the 
review of DOTS registers, so the first (non-MDR) sputum found was used to classify 
patients.  If these patients went on to develop MDR-TB or XDR-TB, they were 
nevertheless kept in the non-MDR-TB group, because the development of MDR-TB or 
XDR-TB in these patients was considered an important outcome.
Finally, patients who were first classified into the MDR and XDR TB groups but 
who were selected randomly through the TB register as non-MDR-TB patients were 
moved to the non-MDR-TB group.
Patients who had multiple susceptibility patterns were included in the bivariate 
and multivariate analyses to examine clinical predictors and outcomes and were also 
examined separately as a case series.
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Data Collection
There were five sources of data utilized in this study: the TB DOTS register; the 
hospital medical record; laboratory data stored on the Department of Health’s server and 
accessible through an intranet; the registry of MDR and XDR-TB patients in the TB 
DOTS clinics; and spreadsheets maintained by the COSH ARV Clinic.  
The TB DOTS register contained treatment category (new patient, retreatment 
after cure, re-treatment after interruption, etc), treatment regimen, sputum smear 
information at 0, 2 and 6 months, and treatment outcomes (cure, treatment completion, 
treatment interruption, transferred out, death).
The patient’s hospital medical record contained the majority of information, 
including demographics, HIV status, clinical and laboratory details from outpatient visits 
and hospitalizations, previous episodes of tuberculosis, date of transfer to a tertiary 
facility for second line drugs, and death certificate. The registry of MDR and XDR-TB 
patients maintained in the TB DOTS clinic contained information on the tracing of 
patients found to have MDR and XDR-TB, including whether the patient was alive or 
deceased at the time of tracing.  Spreadsheets maintained by the COSH ARV Clinic 
contained antiretroviral therapy related information including CD4 counts, viral loads, 
and date of initiation of therapy. 
Data collection from each of these sources was performed by the author and 
entered directly onto a standardized electronic data collection form linked to a Microsoft 
Access 2002 (Microsoft Corp, Redmond, WA, USA) database created by the author and a 
co-investigator (NRG).  Data collected concluded on November 15, 2006; mortality and 
other outcomes were included up until this date.  For patients who were not confirmed to 
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have died, the survival or observation period was taken to conclude at the last point in 
which the patient was documented to have visited the hospital or clinic.
Mycobacterial Culture and Drug Susceptibility Testing Methods
Sputum samples were obtained from all patients for mycobacterial culture and 
drug susceptibility testing as part of routine clinical care and disease surveillance at 
COSH.  Some of the sputa were collected at the time of TB diagnosis as directed by 
hospital procedures during this time; others were collected after the initiation of therapy, 
either due to suspected treatment failure or the lack of sputum collection at the time of 
diagnosis.  The sputum collection, culture, and drug susceptibility testing methods have 
been previously described and published (41): 
Typically, one to three samples were taken per patient. The samples were 
not induced and were taken at any time of day. Sputum specimens were stored at 
4°C for up to 3 days until transport to the provincial diagnostic mycobacteriology 
laboratory in Durban. Digestion and decontamination was done with the N-acetyl-
L-cysteine-sodium hydroxide method. An auramine-stained smear was made and 
the remaining deposit was inoculated in one mycobacteria growth indicator tube 
(MGIT) broth and on one Middlebrook 7H10 agar plate. The broths were
incubated at 37°C in an automated incubator. Agar plates were sealed in CO2-
permeable plastic bags and incubated in 5% CO2 at 37°C. Acid-fast microscopy 
was done on each positive MGIT broth when a positive reading was obtained.
Those containing acid-fast bacilli were subcultured on Middlebrook 7H10 agar. 
Primary Middlebrook agar plates were read weekly for 3 weeks or until growth 
was observed. Microscopy was done to confirm the presence of acid-fast bacilli. 
All positive cultures were identified as Mycobacterium tuberculosis by means of 
niacin and nitrate reductase tests. The risk of cross-contamination was minimized 
by processing samples individually in real time, rather than batching. Quality 
assurance was done weekly by the UK National External Quality Assessment 
Service programme, where ten consecutive isolates were fingerprinted to rule out 
cross-contamination. Susceptibility tests were done on all isolates using the 1% 
proportional method on Middlebrook 7H10 agar. All isolates were tested for 
susceptibility to isoniazid (1 mg/L), rifampicin (2 mg/L), ethambutol (5 mg/L), 
streptomycin (2 mg/L), kanamycin (16 mg/L) and ciprofloxacin (2 mg/L).
Susceptibility testing to pyrazinamide and the remaining four classes of second 
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line drugs—ethionamide, cycloserine, capreomycin, and para-aminosalicylic 
acid—are not routinely done.
Statistical Analysis 
Bivariate analyses were undertaken to compare clinical characteristics between 
drug resistance groups and identify significant associations with mortality among all drug 
resistance groups.  T tests and Wilcoxon tests were used to compare means and medians, 
respectively, and all dichotomous and nominal data were analyzed by Chi-square analysis 
and Fischer’s exact tests.  Kaplan-Meier survival curves were produced to express 
differences in survival between drug resistance groups.  Comparisons in each analysis 
were made between 2 of the 3 groups at a time: non-MDR vs. MDR, MDR vs XDR, and 
non-MDR vs. XDR.
Multivariate logistic regression was used to determine factors independently 
associated with drug resistance.  Similar to the bivariate analysis, comparisons were made 
between 2 of the 3 drug-resistance groups at a time.  Independent factors tested were: 
age, sex, CD4 cell count, hospitalization in the previous 2 years, TB treatment in the 
previous year, and sputum smear.  Cox proportional hazards modeling was used to assess 
factors independently associated with mortality.  Independent factors tested included: 
age, sex, CD4 cell count less than 50, CD4 cell count less than 200, MDR-TB, non-
MDR-TB, XDR-TB, TB treatment in the previous year, and hospitalization in the 
previous year.  A subset of patients who had changes in resistance patterns over the 
survey period were analyzed separately and descriptively as a case series. All analysis 
was performed by the author and a co-investigator (NRG) and done in SAS version 9.1 
(SAS Institute Inc, Cary, NC, USA).  
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Demographics and Clinical Characteristics by Drug Resistance Group
Data for 193 patients were reviewed for the study.  After excluding patients the 
most recent episode of TB was diagnosed and treatment initiated prior to June 1, 2005, 
there were 170 patients remaining in the study.  Fifty-seven patients were classified into 
the non-MDR-TB group, 52 patients were classified into the MDR-TB group, and 61 
patients were classified in the XDR-TB group.  The demographic information and 
baseline clinical characteristics are depicted in Table 1. Of note, women comprised more 
than half of the XDR-TB group (55.7%) and less than half of the non-MDR and MDR 
groups (40.4%, 34.6%).  The difference in sex between the XDR group and the MDR 
group was statistically significant (P=0.025).  Ages were similar between all three 
groups.  The median and range of age for the non-MDR, MDR and XDR groups were 
32.6 (14.7-70.6), 33.7 (19.9-56.9) and 34.5 (15.4-61.4), respectively.
The sputum smear positive rates were 47.4%, 71.2% and 73.8% for non-MDR, 
MDR and XDR patients, respectively.  The differences between the non-MDR and MDR 
and XDR group were statistically significant (P=0.015, P=0.005).  XDR and MDR 
patients had slightly higher rates of extrapulmonary TB (29.5%, 30.8%) compared with 
non-MDR patients (24.6%), but the differences were not statistically significant (P= 
0.469 for MDR versus non-MDR, P=0.546 for XDR versus non-MDR).  At baseline, 
most patients in all three groups had moderate-severe anemia, with median hemoglobin 
in the non-MDR, MDR and XDR groups of 9.0 g/dL, 9.3 g/dL and 9.3 g/dL.  Median 
erythrocyte sedimentation rate (ESR) was elevated in all three groups and higher in the 
non-MDR group (115.5 mm/h) than in the MDR (95 mm/h) and XDR groups (100 
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mm/h), but not significantly so (P=0.187, P=0.272).  Median weights were slightly higher 
for both men and women in the non-MDR groups (53.0 kg, 52.0 kg) compared with the 
MDR only (47.5 kg, 51.0 kg) and XDR groups (49.25 kg, 50.5 kg), but the differences 
between all groups were not statistically significant.  There were no significant 
differences in any groups in terms of reported symptoms of weight loss, cough, night 
sweats, or fever.  
The HIV-related characteristics of patients by drug resistance group are described 
in Table 2. Compared with patients in the MDR group, XDR patients were more likely to 
have been tested for HIV (93.4% versus 76.9%, P= 0.012).  Among non-MDR patients, 
82.5% were tested for HIV, which was not statistically different from the MDR and XDR 
groups.  The HIV prevalence in the non-MDR, MDR, and XDR groups (among tested 
patients) was 93.6%, 92.5%, and 100%, respectively.  The differences in HIV prevalence 
were not statistically significant.  Among individuals co-infected with HIV, 25.0%, 
24.3% and 33.3% of patients in the non-MDR, MDR and XDR groups received 
antiretrovirals at any time; more patients in the XDR group were on antiretroviral therapy 
(ART) at the time of TB diagnosis (14.0%) than in the non-MDR (4.5%) and MDR 
groups (5.4%).  None of the differences in ART use were statistically significant.
Fewer than half of all HIV infected patients had a viral load performed around the 
time of TB diagnosis, and the median log viral load did not differ between the non-MDR, 
MDR and XDR groups (5.6, 5.2 and 5.1).  Of patients on ART at the time of TB 
diagnosis, five patients in the XDR group and none in the MDR and non-MDR groups 
had a viral load result.  Of the five patients in the XDR group on ART, three had 
achieved viral suppression (viral load < 25 copies/mL).
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Among HIV-infected patients, median CD4 cell count at diagnosis (70.5 
cells/mm3) was higher in the non-MDR group than in the MDR only (57 cells/mm3) and 
XDR groups (56 cells/mm3), but the differences were not statistically significant.  When 
CD4 counts were stratified into three groups—less than 50 cells/mm3, 50 to 200 
cells/mm3, and >200 cells/mm3—the proportion of XDR patients with CD4 cell counts 
over 200 (14.3%) was less than that of MDR and non-MDR patients (20.8%, 18.5%), but 
not significantly.
Patients in the MDR and XDR groups were more likely than the non-MDR-TB
group to have any previous TB treatment and TB treatment in the past year (Table 3).  
Among non-MDR, MDR and XDR patients, 26.3%, 56.9% and 42.6% had been 
previously treated for TB.  The difference between MDR and non-MDR patients was 
statistically significant (P<0.001; OR 4.13, 95%CI 1.84-9.28).  MDR-TB patients were 
more likely than XDR-TB patients to have had any previous TB treatment, but this
difference did not reach statistical significance. (P=0.072; OR 1.99, 95% CI 0.94-4.21).  
However, both MDR and XDR patients were significantly more likely to have had TB 
treatment in the past year compared with non-MDR-TB patients (P<0.0001, OR 13.36, 
95% CI 2.91-61.39; P<0.001, OR 10.63, 95% CI 2.33-48.48).  The difference between 
the MDR and XDR groups for TB treatment in the previous year were not statistically 
significant (P=0.577).
Compared with non-MDR patients, MDR and XDR patients were significantly 
more likely to have had any previous hospitalization (42.3% and 41.0% versus 21.1%; 
P=0.017 and P=0.020; OR 2.75 95% CI 1.19-6.38 and OR 2.6 CI 1.15-5.89) and 
hospitalization in the past two years (36.5% and 37.7% versus 14.0%; P=0.007 and 
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P=0.004; OR 3.53, 95% CI 1.38-9.00 and OR 3.71, 95% CI 1.49-9.20).  The proportion 
of patients with previous hospitalizations and hospitalizations in the past two years were 
similar for MDR and XDR groups.
In multivariable analysis comparing the MDR and non-MDR groups (Table 4), 
TB treatment in the previous year was the only significant independent predictor of 
MDR-TB (adjusted OR 8.33, 95% CI 1.64-42.33).  In multivariable analysis comparing 
XDR and non-MDR groups (Table 5), significant independent differences were found for 
TB treatment in the past year (adjusted OR 7.19, 95% CI 1.35-38.17) and sputum smear 
positive (adjusted OR 2.79, 95% CI 1.20-6.47).  Sex was the only significant independent 
factor in the multivariable model comparing the XDR and MDR groups (adjusted for 
male sex OR 0.41, 95% CI 0.19-0.89) (Table 6).  Hospitalization in the past two years 
and patient age were not statistically significant risk factors for any of the groupings 
under this analysis.
Mortality
The overall mortality rates in the non-MDR, MDR and XDR groups were 36.8%, 
73.1% and 85.3%, respectively.  Survival by drug resistance group from time of TB 
treatment start is depicted by Kaplan-Meier curve in Figure 1.  Median survival times for 
the non-MDR, MDR and XDR groups under Kaplan-Meier analysis (limiting survival 
time among censored to the follow-up period) were 199 days, 103 days, and 92 days, 
respectively.  The median follow-up period from time of TB diagnosis among surviving 
patients was shorter in the non-MDR group (median 52.5 days, interquartile range (IQR) 
10-262.5 days) than in the MDR only group (median 119 days, IQR 99-282 days) and 
XDR group (median 161 days, 84-181 days).  Survival by drug resistance group from 
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time of collection of diagnostic sputum (for culture and DST) is shown in Figure 2.  
Median survival times for the non-MDR, MDR and XDR groups from sputum collection 
were 190 days, 22 days, and 14 days, respectively.
Table 7 shows demographic and baseline clinical characteristics among patients 
surviving and those who died.  In bivariate analysis, there were no differences in sex or 
age between patients who died and those who survived or whose outcome was unknown.  
Patients with combined extrapulmonary and pulmonary TB were more likely to die than 
those with pulmonary TB alone, though the difference was not statistically significant
(P=0.095, OR 1.88, 95% CI 0.89-3.97); mortality was 75% with patients with 
extrapulmonary TB (36/48 patients).  Patients who died were more likely to be sputum 
smear positive (71.2% versus 50.8%, P=0.007).  Median hemoglobin and ESR at baseline 
were not significantly different.  Median weight at baseline was lower for both men and 
women among patients who died, but the differences were not significant (51.0 kg versus 
52.0 kg, P=0.40; 48.3 kg versus 53.0 kg, P=0.111).
There was no difference between the proportion of patients tested for HIV 
between those who died and survived (85.6%, 83.1%; P=0.662) (Table 8).  The HIV 
prevalence was slightly higher, but not statistically so, among patients who died (96.8% 
versus 93.9%; P=0.409).  The proportion of patients on ART at the time of TB diagnosis 
did not differ significantly between those who died and those who did not (9.8% versus 
6.5%, P=0.522), but the proportion of those who ever received ART was higher in those 
who survived (39.1% versus 22.8%, P=0.049).  Median log viral load at time of TB 
diagnosis did not differ between those who died and survived (5.23 versus 5.28, P=0.82).  
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Viral load measurements on ART at the time of TB diagnosis were available for five 
patients total; among four who died, two had viral load suppression.
A little over half of patients in both outcome groups had CD4 counts within 120 
days of TB diagnosis; median CD4 count was lower in the group who died, but the 
difference was not significant (53.5 cells/mm3 versus 104 cell/mm3; P=0.552).  Patients 
who died were more likely to have a CD4 count less than 50 cells/mm3 (48.1% versus 
28.0%, P=0.004) and less than 200cells/mm3 (90.7% versus 64.0%, P=0.004).  The odds 
ratios of death among patients with <50 cells/mm3 or 50-200 cells/mm3 compared with 
>200 cells/mm3 were 6.69 (95% CI 1.69-26.45) and 4.60 (95% CI 1.21-17.52) 
respectively.
The relationship between previous TB treatment and previous hospitalization and 
mortality is shown in Table 9.  The proportion of patients who had ever been treated for 
TB did not differ between those who died and survived (44.1% versus 39.0%, P=0.517); 
the proportion with treatment in the last year was higher, but not significantly, among 
those who died (25.2% versus 13.6%, P=0.076).  There was a trend indicating that 
patients who died were more likely to have been hospitalized ever (39.6% versus 25.4%, 
P=0.064) or in the previous year (27.9% versus 15.3%, P=0.064).
Under the Cox Proportional Hazards model (Table 10), mortality from TB 
treatment start was independently and significantly associated with positive sputum 
smear (HR 2.09, P=.003), MDR-TB (HR 2.00, P=0.028), XDR-TB (HR 2.50, P=0.002), 
and CD4 cell count less than 200 cells/mm3 (HR 3.23, P=0.037).  In the Cox model 
examining mortality from time of diagnostic sputum collection (Table 11), all of these 
associations were greater in magnitude and statistical significance: positive sputum smear 
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(HR 2.36, P<0.001); MDR-TB (HR 3.09, P<0.001); XDR-TB (HR 4.31, P<0.0001); and 
CD4 cell count less than 200 cells/mm3 (HR 4.69, P=0.006).  Patient age, sex, 
extrapulmonary tuberculosis, treatment in the previous year, admission in the previous 
year, and CD4 cell count less than 50 cells/mm3 all failed to achieve statistical 
significance in this model.
Drug Resistance Patterns Among Isolates
Of the 170 patients included in the study, 125 (74%) had a single drug-
susceptibility testing (DST) pattern which remained unchanged over their treatment 
course.  Of the remaining 45 patients, 34 had isolates with two different DST patterns, 10 
had three DST patterns, and one had four DST patterns.  
A total of 229 isolates with differing DST patterns were cultured from the 170 
patients in this study (Table 12).  These consisted of 74 non-MDR isolates, 70 MDR 
isolates and 85 XDR isolates.  Among the 74 non-MDR isolates, 66 (89%) were fully 
susceptible, 7 (9%) were mono-resistant (5 to isoniazid (INH), 2 to rifampicin (RIF)), and 
one (1%) was poly-resistant (INH and streptomycin (SM)).  Among the 70 MDR isolates, 
17 (24%) were resistant to only INH and RIF.  Resistance to INH, RIF and SM (42/70, 
60%) was the most common MDR resistance pattern.  None had resistance to only INH, 
RIF and ethambutol (EMB), and 6 had resistance to INH, RIF, EMB and SM.
  Of the 85 XDR-TB isolates, 21 (26%) were resistant to INH, RIF, ciprofloxacin 
(CPX) and kanamycin (KM) only.  Six 6 (7.5%) were resistant to INH, RIF, CPX, KM 
and EMB but not SM, and 24 (30%) were resistant to INH, RIF, CPX, KM and SM but 
not EMB.  Thirty-four (42.5%) were resistant to all six drugs tested.
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Changes in Drug Resistance Patterns
Forty-five patients had multiple sputum susceptibility patterns in the study period, 
of which 30 patients had sputum isolates that fell into two or more resistance categories 
(MDR-TB, XDR-TB or non-MDR-TB) (Figure 3).  Of the thirty patients with sputum 
isolates in more than one resistance group, 18 went from a lower to a higher resistance 
group over time (e.g. non-MDR to MDR), 8 had isolates from the same week in two 
different resistance groups, and 4 went from a higher to a lower resistance group (e.g. 
XDR to MDR).
Among the 18 patients who had initial isolates in a lower resistance category 
followed by later isolates in a higher resistance category, 7 went from non-MDR to 
MDR, 8 went from non-MDR to XDR, 1 went from MDR to XDR, and 2 went from non-
MDR to simultaneous MDR and XDR (Table 13).  Among the seven patients having a 
non-MDR isolate and a subsequent MDR isolate, the mean time between isolates was 146 
days (range 69-222 days).  Among those having a non-MDR isolate followed by a XDR 
isolate, the mean time between isolates was 109.5 days (range 69-183 days).  For the two 
patients who had a non-MDR isolate followed by simultaneous isolates of MDR and 
XDR-TB, the mean time was 191 days (153, 299 days).
For the single patient who had an MDR-TB isolate followed by an XDR-TB 
isolate, the duration between the isolates was 260 days; the patient received 
INH,RIF,EMB,SM and pyrazinamide (PZA) for three and a half weeks, followed by 
second line drugs (ofloxacin, ethionamide, pyrazinamide, amikacin, ethambutol ).  SLD 
were given two months after the isolate for MDR-TB (INH, RIF resistance) and five 
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months before the isolate for XDR-TB (INH, RIF, SM, CPX, KM resistance) was 
collected.
Six of the seven patients with a fully susceptible TB in their first isolate and MDR 
in their subsequent isolate had resistance to SM as well, despite never having received 
SM during that period.  All of the patients whose DST pattern changed from non-MDR to 
XDR were hospitalized at some point during the period between collection of the isolates, 
suggesting the possibility of exogenous super-infection with a more drug-resistant strain.
Two patients with MDR had increasing drug resistance: one patient had INH and 
RIF resistance at baseline and INH, RIF, SM, CPX and KM (XDR-TB) after 260 days; 
the other patient had INH and RIF resistance at baseline, followed by INH, RIF, SM and 
KM resistance (still MDR-TB) after 33 days.
Seventy-four percent (52/70) of MDR-TB isolates had SM resistance, and 60% 
(42/70) of all MDR-TB isolates had the same DST pattern of resistance to INH, RIF and 
SM, despite the fact that few patients had exposure to SM.  Only 5 patients with MDR-
TB had prior streptomycin exposure (all had resistance to SM at baseline).  An additional 
nine patients with MDR-TB received SM as part of initial therapy during the study 
period, among whom only four had SM resistant isolates at baseline.  Of these four, two 
of the sputa were collected within two weeks of treatment start (2 days, 11 days), making 
acquired resistant highly improbable.  The other two were collected 55 and 68 days after 
start of treatment.  No patients receiving streptomycin were observed to have a previously 
streptomycin susceptible sputum followed by a streptomycin resistant sputum.
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Table 1  Demographics and Baseline Clinical Characteristics and Symptoms by Drug Resistance Group
Non-MDR MDR XDR P Values
Total, N 57 52 61 MDR / XDR / XDR /
Non-MDR Non-MDR MDR
Sex
Women, n (%) 23 (40.4) 18 (34.6) 34 (55.7) 0.537 0.095 0.025
Age, years
Mean (S.D.) 34.5 (10.1) 35.4 (8.3) 35.1 (7.8)
Median (range) 32.6 (14.7-70.6) 33.7 (19.9-56.9) 34.5 (15.4-61.4) 0.420 0.350 0.947
Sputum Smear
Positive, n (%) 27 (47.4) 37 (71.2) 45 (73.8) 0.015 0.005 0.756
Extrapulmonary TB§
Present, n (%) 14 (24.6) 16 (30.8) 18 (29.5) 0.469 0.546 0.884
Hemoglobin (g/dL), n 45 43 53
Median (IQR) 9.0 (7.5-10.5) 9.3 (8.0-11.4) 9.3 (7.8-10.8) 0.237 0.435 0.602
ESR (mm/h), n 28 32 37
Median (IQR) 115.5 (74-130) 95.0 (53.5-126.5) 100.0 (55-123) 0.187 0.272 0.834
Weight (kg)
Women, n 15 12 16
Median (IQR) 53.0 (46.0-60.0) 47.5 (45.0-54.8) 49.25 (43.6-54.0) 0.338 0.252 0.945
Men, n 24 21 22
Median (IQR) 52.0 (48.0-54.5) 51.0 (45.0-54.0) 50.5 (47.0-60.0) 0.455 0.870 0.301
Weight Loss
Yes, n (%) 35 (61.4) 33 (63.5) 36 (59.0) 0.918 0.783 0.707
Cough
Yes, n (%) 46 (80.7) 39 (75.0) 49 (80.3) 0.365 0.802 0.497
Night Sweats
Yes, n (%) 18 (31.6) 16 (30.8) 23 (37.7) 0.878 0.529 0.440
Fever
Yes (n,%) 25 (43.9) 19 (36.5) 27 (44.3) 0.392 0.967 0.405
§ All patients had pulmonary TB as well.  Extrapulmonary TB patients had pulmonary
  and extrapulmonary disease.
Statistically significant values are in bold.
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Table 2 HIV-related Clinical Information By Drug Resistance Group
MDR / XDR / XDR /
Non-MDR MDR XDR Non-MDR Non-MDR MDR
Total, N 57 52 61
P Values
Tested For HIV
n (%) 47 (82.5) 40 (76.9) 57 (93.4) 0.472 0.065 0.012
HIV Positive
n (% of tested) 44 (93.6) 37 (92.5) 57 (100) 1.000 0.089 0.067
On ART
Before TB Diagnosis
n (% of HIV+) 2 (4.5) 2 (5.4) 8 (14.0) 1.000 0.180 0.306
Ever
n (% of HIV+) 11 (25.0) 9 (24.3) 19 (33.3) 0.944 0.334 0.323
VL at Diagnosis*
n 8 13 20
Log Median (IQR) 5.6 (5.0-6.1) 5.2 (4.6-6.0) 5.1 (3.2-5.7) 0.690 0.177 0.269
n on ART (VL<25) 0 0 5 (3)
CD4 at Diagnosis*
n 24 27 28
median (IQR) 70.5 (36-131.5) 57 (34-104) 56 (19-156.5) 0.461 0.344 0.561
<50 (n,%) 9 (37.5) 12 (44.4) 12 (42.9) 0.777 0.781 1.000
50-200 (n,%) 10 (41.7) 10 (37.0) 12 (42.9) 0.780 1.000 0.785
>200 (n,%) 5 (20.8) 5 (18.5) 4 (14.3) 1.000 0.716 0.729
VL = Viral Load; OR = Odds Ratio; IQR = Interquartile Range; CI= Confidence Interval; ART = Antiretroviral Therapy
*Values were included if performed within 120 days of start of TB treatment
CD4 counts are cells / mm3; Viral Load is expressed in copies per mL
Statistically significant values are in bold.
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Table 3 Previous TB Treatment and Previous Hospitalizations by Drug Resistance Group
MDR / XDR / XDR /
Non-MDR MDR XDR Non-MDR Non-MDR MDR
Total, N 57 52 61 OR
(95% CI)
Previous TB Treatment
Any, n (%) 15 (26.3) 31 (59.6) 26 (42.6) 4.13 2.08 0.50
(1.84-9.28) (0.96-4.53) (0.24-1.07)
Past Year, n (%) 2 (3.5) 17 (32.7) 17 (27.9) 13.36 10.63 0.80
(2.91-61.39) (2.33-48.48) (0.36-1.78)
Previous Hospitalization
Any, n (%) 12 (21.1) 22 (42.3) 25 (41.0) 2.75 2.6 0.95
(1.19-6.38) (1.15-5.89) (0.45-2.01)
Past 2 Years, n (%) 8 (14.0) 19 (36.5) 23 (37.7) 3.53 3.71 1.02
(1.38-9.00) (1.49-9.20) (0.47-2.20)
Previous hospitalizations were not limited to admissions for TB.
Statistically significant values are in bold.
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Table 4 Risk Factors for MDR-TB in Logistic Regression Model (comparison with non-MDR-TB)
Unadjusted OR 95% CI Adjusted OR 95%CI
Male Sex 1.28 0.59-2.78 1.24 0.52-3.00
TB Treatment in Last Year 13.36 2.91-61.39 8.33 1.64-42.33
Hospitalized in Last 2 Years 3.53 1.38-9.00 1.69 0.56-5.09
Sputum Smear Positive 2.74 1.24-6.06 1.59 0.66-3.81
Statistically significant values are in bold.
Table 5 Risk Factors for XDR-TB in Logistic Regression Model (comparison with non-MDR-TB)
Unadjusted OR 95% CI Adjusted OR 95%CI
Male Sex 0.54 0.26-1.12 0.45 0.20-1.03
TB Treatment in Last Year 10.63 2.33-48.48 7.19 1.35-38.17
Hospitalized in Last 2 Years 3.71 1.49-9.20 1.81 0.62-5.25
Sputum Smear Positive 3.13 1.44-6.76 2.79 1.20-6.47
Statistically significant values are in bold.
Table 6  Risk Factors for XDR-TB in Logistic Regression Model (comparison with MDR-TB)
Unadjusted OR 95% CI Adjusted OR 95%CI
Male Sex 0.42 0.20-0.90 0.41 0.19-0.89
TB Treatment in Last Year 0.8 0.36-1.78 0.79 0.31-2.00
Hospitalized in Last 2 Years 1.02 0.47-2.20 1.19 0.49-2.86
Sputum Smear Positive 1.14 0.50-2.61 1.39 0.56-3.42
Statistically significant values are in bold.
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Table 7  Demographics and Baseline Clinical Characteristics by Outcome
Died Alive/Unknown P Values
Total, N 111 59
Sex
Female, n (%) 50 (45.0) 25 (42.4) 0.738
Age
Median (IQR) 33.9 (29.4-39.9) 33.4 (27.9-39.1) 0.480
Extrapulmonary TB
Present, n (%) 36 (32.4) 12 (20.3) 0.095
Sputum Smear
Positive, n (%) 79 (71.2) 30 (50.8) 0.007
Hemoglobin (g/dL), n 95 46
Median (IQR) 9.1 (7.8-10.6) 9.3 (7.5-11.2) 0.958
ESR (mm/h), n 63 34
Median (IQR) 99 (57-123) 114 (60-130) 0.354
Weight (kg)
Women, n 26 17
Median (IQR) 48.3 (45-53.5) 53 (46-60) 0.111
Men, n 44 23
Median (IQR) 51.5 (46-54.5) 52 (45-56) 0.400
Statistically significant values are in bold.
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Table 8  HIV-related Clinical Information by Outcome
Died Alive/Unknown
P 
Values OR (95% CI)
Total, N 111 59
Tested for HIV
n (%) 95 (85.6) 49 (83.1) 0.662
HIV Positive
n (% of tested) 92 (96.8) 46 (93.9) 0.409 2.00 (0.39-10.30)
On ART
Total
n (% of HIV+) 21 (22.8) 18 (39.1) 0.049 0.44 (0.21-0.95)
Before TB Diagnosis
n (% of HIV+) 9 (9.8) 3 (6.5) 0.522 1.50 (0.39-5.83)
CD4 at TB Diagnosis*
n (% of HIV+) 54 (58.7) 25 (54.3)
Median (IQR) 53.5 (25-95) 104 (41-225) 0.552
<50 26 (48.1) 7 (28.0) 0.004 6.69 (1.69-26.45)
50-200 23 (42.6) 9 (36.0) 0.021 4.60 (1.21-17.52)
>200 5 (9.3) 9 (36.0) 0.004 Referent
VL at TB Diagnosis*
N 29 12
Log Median 5.23 (4.63-5.89) 5.28 (2.45-5.82) 0.82
n on ART (VL < 25) 4 (2) 1 (1)
VL = Viral Load; OR= Odds Ratio; CI= Confidence Interval; IQR = Interquartile Range
*Values were included if performed within 120 days of start of TB treatment
CD4 counts are cells / mm3; Viral Load is expressed in copies per mL
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Table 9  Previous TB Treatment and Previous Hospitalizations by Outcome
Died Alive/Unknown P Values OR (95% CI)
Total, N 111 59
Previous TB Treatment
Any, n (%) 49 (44.1) 23 (39.0) 0.517
1.24 (0.65-
2.35)




Any, n (%) 44 (39.6) 15 (25.4) 0.064
1.93(0.96-
3.87)
Past Years, n (%) 31 (27.9) 9 (15.3) 0.064
2.15(0.95-
4.90)
*Previous hospitalizations were not limited to admissions for TB.
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Table 10   Risk Factors for Mortality from Start of TB Treatment
in Cox Proportional Hazards Model
HR 95% CI P value
Male Sex 0.90 0.45-1.35 0.658
TB Treatment in Last Year 1.60 1.08-2.12 0.077
Hospitalized in Last Year 1.57 1.08-2.06 0.073
Sputum Smear Positive 2.09 1.60-2.58 0.003
XDR-TB 2.50 1.92-3.08 0.002
MDR-TB 2.00 1.38-2.62 0.028
CD4 less than 200/mm3 3.23 2.13-4.33 0.037
Statistically significant values are in bold.
Table 11 Risk Factors for Mortality from Time of Diagnostic Sputum
Collection in Cox Proportional Hazards Model
HR 95% CI P value
Male Sex 1.09 0.64-1.54 0.718
Treatment in Last Year 1.29 0.78-1.80 0.321
Hospitalized in Last Year 1.24 0.76-1.72 0.378
Sputum Smear Positive 2.36 1.88-2.84 <0.001
XDR-TB 4.31 3.71-4.91 <0.0001
MDR-TB 3.09 2.47-3.71 <0.001
CD4 less than 200/mm3 4.69 3.59-5.79 0.006
Statistically significant values are in bold.
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Table 12  Drug Resistance Patterns Found and Their Frequencies
Resistance Class Drug Resistance Pattern Frequency, n*
Drug Susceptible -- 66
Monoresistant INH 5
RIF 2
Polyresistant INH, SM 1
Multidrug-Resistant INH, RIF 17
INH, RIF, SM 42
INH, RIF, KM 1
INH, RIF, SM, KM 2
INH, RIF, EMB, SM 6
INH, RIF, EMB, SM, CPX 2
Extensively Drug-Resistant INH, RIF, CPX, KM 21
INH, RIF, CPX, KM, EMB 6
INH, RIF, CPX, KM, SM 24
INH, RIF, CPX, KM, EMB, SM 34
Total 229
INH = Isoniazid; RIF = Rifampicin; EMB = Ethambutol;
SM = Streptomycin; CPX = Ciprofloxacin; KM = Kanamycin
* Multiple isolates from the same patient with the same resistance pattern were
  only counted once
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Table 13   Drug Resistance Patterns and Timing of Isolate Collection for Patients with Multiple
Resistance Patterns Conferring Changes in Resistance Category
Days Days Days Days
Isolate 1 Iso 1 to Isolate 2 Iso 2 to Isolate 3 Iso 3 to Isolate 4 Iso 4 to Isolate 5
Pt Outcome Resist. Iso 2 Resist. Iso 3 Resist. Iso 4 Resist. Iso 5 Resist.
non-MDR to MDR Only
1 death none 137 HRS -- -- -- -- -- --
2 death none 175 HRES -- -- -- -- -- --
3 death none 78 HRS -- -- -- -- -- --
4 death none 69 HRS -- -- -- -- -- --
5 alive none 187 HR -- -- -- -- -- --
6 death none 6 none 222 HRS -- -- -- --
7 death none 154 HRES 0 HRS -- -- -- --
non-MDR to XDR
8 death none 94 HRCK -- -- -- -- -- --
9 death none 101 HRSCK 1 HRSCK 0 HRESCK -- --
10 death none 69 HRESCK -- --
11 unknown none 48 none 132 HRESCK 72 HRESCK 0 HRSCK
12 Alive none 80 HRCK -- -- -- -- -- --
13 Death none 183 HRESCK -- -- -- -- -- --
14 Death none 32 none 68 HRCK -- -- -- --
15 Death none 6 none 63 HRSCK -- -- -- --
non-MDR to MDR/XDR
16 Death none 153 HRS 0 HRSCK -- -- -- --
17 Death none 229 HRK 0 HRESCK -- -- -- --
MDR to XDR
18 alive HR 260 HRSCK -- -- -- -- -- --
Pt = Patient; Iso = Isolate; Resist. = Resistance
Days Iso 1 to Iso 2 = Days between collection of isolate 1 and isolate 2
H = Isoniazid; R = Rifampicin; E = Ethambutol; S = Streptomycin; C = Ciprofloxacin; K = Kanamycin
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*Kaplan-Meier survival analysis.  Patients were censored (no longer represented) in the survival curve at 
the last point in time in which they were seen by a health provider.
Figure 1  Survival by Drug Resistant Group from TB Treatment Start*
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*Kaplan-Meier survival analysis.  Patients were censored (no longer represented) in the survival curve at 
the last point in time in which they were seen by a health provider.  Sputum collection refers to the 
collection of the sputum for culture and DST that was used for assignment to a drug resistance group (non-
MDR, MDR or XDR). 
Figure 2  Survival by Drug Resistance Group from Sputum Collection Time*
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1Resistance categories were MDR-TB, XDR-TB and non-MDR-TB as previously 
defined.
All Patients in Study (N=170)
Patients with Multiple Resistance 
Patterns During Study Period 
(n=45)
Patients with Only One
Resistance Pattern 
During Study Period (n=125)
Patients with Isolates from Two 
or More Resistance Categories1 
(n=30)
Patients with Multiple Isolates from 
Same Resistance Category1 (n=15)
Patients with Increasing 
Resistance (n=18)
Non-MDR to MDR (7)
Non-MDR to XDR (8)
Non-MDR to MDR and XDR (2)
MDR to XDR (1)




Patients with Decreasing 
Resistance (n=4)
XDR to MDR (1)
MDR to Non-MDR (3)
Figure 3  Patients with Multiple Resistance Patterns During Study Period 
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DISCUSSION
In this study in rural KwaZulu Natal, South Africa, we performed detailed 
analysis of cases of drug sensitive and drug resistant TB.  In our previous report of XDR-
TB in this setting (41), we found near universal mortality, occurring in a median of 16 
days after sputum was obtained for TB culture. Many patients received the diagnosis 
post-mortem and most had the opportunity to transmit resistant organisms to others 
before diagnosis was made. These observations illustrated the critical need for early 
identification of patients with drug resistant TB and prompted this study. Due in part to 
the paucity of laboratory capacity for DST in Sub-Saharan Africa, there have been few 
reports of clinical predictors of MDR-TB in the high TB prevalence and high HIV 
prevalence settings of this region.  We sought to further characterize the clinical 
manifestations and outcomes of XDR-TB and MDR-TB with comparison to non-MDR-
TB in order to identify characteristics that might result in earlier diagnosis.  Our results 
have provided some information which might be of clinical utility in this regard. We 
confirmed the high mortality associated with XDR-TB in this setting and found high rates 
of mortality among patients with MDR-TB as well.  More than ninety percent of tested 
patients in all groups were HIV-infected, and a positive sputum smear was independently 
associated with both drug resistance and mortality in this population.  Previous TB 
treatment in the last year and hospitalization in the past two years predicted drug resistant 
TB.  MDR-TB appeared to be more often due primary drug resistance, including super-
infection of fully susceptible TB, than acquisition of drug resistance.  Amplification of 
resistance among patients with MDR-TB and XDR-TB was not widely observed.  This 
study and the findings noted above represent the first description of clinical 
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characteristics of patients with extensively drug-resistant tuberculosis and the first 
comparative examination of risk factors and outcomes for non-MDR, MDR and XDR-
TB.  
Clinical Predictors of MDR-TB and XDR-TB
Clinical predictors of MDR-TB and XDR-TB did not differ significantly, and 
apart from the interesting association with positive sputum smear, were consistent with 
previously described risk factors for drug resistant tuberculosis.  The strongest clinical 
predictors of drug resistant tuberculosis (both MDR-TB only and XDR-TB) were TB 
treatment in the previous year, hospitalization in the previous two years and positive 
sputum smear.  In numerous studies of risk factors for drug-resistant TB, previous TB 
treatment—particularly in the context of treatment default, treatment failure, or relapsed 
TB—has been consistently found to predict MDR-TB (67-74).  Studies comparing drug 
susceptible TB and MDR-TB have found previous TB treatment to be associated with 
odds ratios ranging from 2 to more than 10.  Data on outcomes of previous TB treatment
were not available for this study.  However, studies have found that even among MDR-
TB patients found to be cured under short-course chemotherapy, 30% subsequently 
relapsed (113), suggesting that previous treatment cure may not reliably exclude drug-
resistant TB.
While there was a strong association between previous TB treatment and drug-
resistant TB, it is of great importance to note our finding that 40% of MDR-TB patients 
and nearly 60% of XDR-TB patients had no previous TB treatment.  Moreover, the 
majority of MDR-TB patients had streptomycin resistance without previous exposure to 
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streptomycin.  Together, these findings suggest that much—if not the majority—of 
MDR-TB in this setting is due to transmitted (or primary) drug resistance.
Previous treatment for MDR-TB may not only represent acquisition of drug 
resistant TB (by incomplete or inappropriate treatment), the sense in which previous 
treatment is usually assumed to be a risk factor in many of the aforementioned studies.  
Rather, this association between previous treatment and MDR-TB may, in part, be 
understood similarly to the association between previous treatment and XDR-TB (the 
proportion with previous treatment in the MDR-TB and XDR-TB groups were not 
statistically different), which can be explained as follows.  Since no XDR-TB patients 
had prior exposure to second-line drugs (SLD), XDR-TB was likely all primary 
resistance.  The association with previous treatment was likely due to two causes: many 
XDR-TB patients were treated with first-line drugs at first TB diagnosis because DST 
wasn’t performed; and previous TB diagnosis resulted in hospitalization, which was a 
risk factor for super-infection with XDR-TB.  While some MDR-TB may have been 
attributable to acquired drug resistance from previous failed treatment, much of the 
association with previous treatment may be explained by this other mechanism.
Previous hospitalization and hospitalization in the past two years were significant 
risk factors for MDR-TB and XDR-TB on bivariate analysis but were not found to be 
significant independent risk factors on multivariate analysis.  The association between 
previous hospitalization and development of drug resistant tuberculosis may be expected 
due to the favorable conditions for nosocomial spread of drug resistant TB at COSH; 
however, the independence of previous hospitalization from previous TB treatment as 
risk factors might not have emerged due to the fact that the greatest risk for nosocomial 
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transmission is on the TB wards, and for hospitalized patients to be at great risk of 
acquiring MDR or XDR-TB, they would have to be undergoing treatment for TB (on 
these and not other wards).  Notably, among the ten patients with pan susceptible isolates 
who later had an XDR-TB isolate (Table 13), all were hospitalized between the collection 
of the two isolates.
Overall, 88% of patients were hospitalized at the time of admission, and median 
hospitalization for non-MDR patients was 13 days. Even during this relatively short stay, 
these patients might have encountered drug resistant TB.  At present, there is inadequate 
hospital space to provide for isolation of patients with unknown TB resistance patterns, 
so patients with drug resistant TB (whose status is usually unknown initially) are first 
admitted to the general TB ward with all other TB patients.  Reserving hospital admission 
to TB wards for patients who are critically ill and shortening hospitalization times may 
reduce the risk of nosocomial transmission of drug resistant TB.
Female sex was a statistically significant independent risk factor for XDR-TB 
compared with MDR-TB.  There is a lack of additional social analysis necessary to fully 
explore this association; simple potential explanations that may have contributed to this 
finding include higher rates of XDR-TB transmission on the Female TB wards, 
documented higher rates of HIV among women in this region, and the high rates of 
seasonal labor migration among men, which could either cause them to be 
disproportionately represented in non-MDR-TB patients while providing a protective 
factor of being away from a community or hospital with high levels of XDR-TB 
transmission.
59
The proportion of patients with a positive sputum smear was higher among XDR-
TB and MDR-TB patients than among non-MDR-TB patients.  This differential rate may 
be in part due to period in time between start of TB treatment and collection of sputum 
for smear and culture (median 7.5 days, third quartile 68 days); patients with non-MDR-
TB would be likely to have a reduction in their bacillary load through standard first-line 
therapy during this time, while patients with MDR-TB and XDR-TB would be less likely 
to achieve this suppression. Sputum smear detection typically requires 5,000-10,000
organisms per milliliter, while culture can detect as low as 10-100 viable organisms per 
milliliter (114). Therefore culture could still be positive in the non-MDR-TB patients 
while smear may have already turned negative.  The proportion of patients with positive 
smear in the MDR and XDR-TB groups in this study were higher than values reported in 
the literature for HIV patients, and 90% of patients in both groups were HIV positive.  
Elliott et al. found 43% and 24% of HIV-infected and uninfected patients with culture 
proven TB to be sputum smear negative (98).  Other studies have found higher 
proportions of sputum negative TB among HIV-infected patients compared with HIV 
uninfected patients, but not necessarily in the context of culture positive TB (for example, 
due to extrapulmonary TB) (115).  Finally, this finding may represent more severe 
disease (e.g. cavitary disease) among MDR-TB and XDR-TB patients, many of whom 
had prior TB treatments and may have been identified later in their course of disease.
The prevalence of HIV did not differ greatly between the three drug resistance 
groups and for all groups was slightly higher than the reported prevalence of HIV among 
TB patients in the province; not all patients were tested for HIV, however, and 
geographic variability of HIV prevalence within the province may partially explain these 
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findings.  There were no HIV negative XDR-TB patients in the study.  While the 
literature has failed to confirm HIV as an independent risk factor for MDR-TB, higher 
rates of HIV among XDR-TB patients would be expected if we assume all of this to be 
recent, primary transmission of drug resistant TB.  Because HIV infected individuals are 
more likely to manifest TB disease within the first year after infection, they would be 
over-represented in the early phases of this emerging drug resistant-TB epidemic 
compared to non-HIV-infected individuals, who have a lower chance of progressing to 
primary disease following initial infection.  Moreover, HIV infected patients are 
overrepresented on hospital wards and are more likely to be admitted with TB disease 
than HIV-uninfected patients; this puts them at increased risk for nosocomial acquisition 
of XDR-TB.
Predictors of Mortality
Mortality was high for all three drug resistance groups. While mortality was 
greater and median survival shorter for XDR-TB patients than MDR-TB only patients, 
the difference was not significant, and the two groups had remarkably similar survival 
trajectories on Kaplan-Meier analysis (see Figure 1).  This may be in part due to the fact 
that survival prior to receipt of SLD may be very similar for MDR compared to XDR-TB 
patients. For XDR-TB patients with susceptibility to ethambutol, first line therapy would 
contain an equal number of active agents against this form of XDR-TB as would be 
available to those with MDR-TB (ethambutol and possibly pyrazinamide).  
In our previous report, medial survival for XDR-TB patients was 16 days from 
time of sputum collection (41).  In this study, median survival from sputum collection 
was 14 days for XDR-TB, 22 days for MDR-TB and 190 days for non-MDR-TB.  
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Therefore, for MDR-TB and XDR-TB patients, median survival is still shorter than the 
period of time required for DST results to be available; that is, most patients died before 
their diagnosis was made.  Median survival from time of TB treatment start was much 
longer for MDR-TB and XDR-TB patients; there are two explanations for this.  One is 
that, despite the hospital’s policy of collecting sputum for culture and DST on all patients 
at time of diagnosis, there was a lag time between TB diagnosis and sputum collection.  
The median time between treatment start and diagnostic sputum collection was 14 days 
and 34 days for MDR-TB and XDR-TB patients, respectively.  The second explanation is 
that some patients with MDR-TB and XDR-TB had drug susceptible TB at the start of 
treatment and acquired MDR-TB or XDR-TB during their initial hospitalization (we 
found evidence of this in the limited number of patients with multiple sputum isolates).  
The survival from sputum diagnosis in these patients would more accurately reflect the 
course of disease for MDR and XDR-TB.  
Significant independent predictors of mortality included MDR-TB only group, 
XDR-TB group, CD4 cell count less than 200 cells/mm3 and positive sputum smear.  
Neither previous TB treatment in the past year nor previous hospitalization in the past 
year were statistically significant predictors of mortality on bivariate or multivariate 
analysis, though both were higher among those who died, with the effect just above the 
level of statistical significance.  The hazard ratio of mortality from sputum collection for 
patients with CD4 cell count less than 200 cells/mm3 was 4.67, highlighting the 
importance of treating HIV disease as a strategy for blunting the impact of tuberculosis 
and drug-resistant tuberculosis.  Studies have shown that antiretroviral therapy, 
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particularly if initiated early, can reduce mortality from TB, as well as TB incidence
(116, 117). 
The fact that positive sputum smear was found to be a significant risk factor for 
mortality on bivariate analysis was not unexpected given the finding of higher rates of 
positive sputum smear among MDR and XDR patients; however, it was surprising to see 
it emerge as a risk factor in the multivariate model.  Smear negative tuberculosis has been 
associated with higher rates of mortality, particularly among HIV-infected individuals 
and in the context of severe immune compromise (5, 118).  This finding may again 
reflect severity of disease, whereby smear positive patients were more likely to have been 
identified later in their course of illness; moreover, given that most sputa for smear were 
collected after initiation of therapy, a negative sputum smear may have reflected early 
smear conversion in some cases.  Chest radiograph review was not performed, but may 
help in further clarifying this association.
Patients in the surviving group were significantly more likely to receive ART; 
however, it is difficult to discern whether this represents an actual survival benefit 
accorded by the use of antiretrovirals or the fact that those surviving had a longer period 
in which to access antiretrovirals.  In patients with a new diagnosis of TB and a CD4 
count over 50 cells/mm3, ART is often deferred for two months, until the end of intensive 
phase of tuberculosis therapy.  Those surviving for more than two months would thus 
have a greater chance of receiving ART.
The mortality rate among MDR-TB only patients (73.1%) was high in comparison 
to values in the literature (107).  Only 19% of MDR-TB patients received second-line 
drugs, due in part to early mortality and loss to follow-up of patients.  All patients are 
63
provided SLD through the public hospital system; however, given that the median time to 
sputum collection was 2 weeks, DST results take three to six weeks, and the median 
survival among all MDR patients was around three months, many patients died before 
accessing SLD.  Even among patients receiving SLD for MDR-TB, a case series from 
South Africa found treatment success rates of 47% for HIV negative patients and 38% for 
HIV positive patients, both well under the norm for WHO DOTS Plus programs (107).
The mortality rate for non-MDR-TB patients (36.8%) was consistent with the 
values in the literature for mortality (around 40%) among TB patients with untreated HIV 
in the region (5). However, the follow-up was poor for non-MDR patients in particular, 
with subsequent hospitalization or death being the most common reasons for having 
follow-up data on these patients, thereby biasing the Kaplan-Meier curves towards 
mortality by having little follow-up among surviving patients.  The high mortality and 
similarity to that of untreated HIV disease may be related to the fact that only 20% 
received ART, as many patients were lost to follow-up.  Furthermore, two patients from 
the non-MDR-TB group went on to develop MDR-TB, and both died; four patients from 
this group went on to develop XDR-TB, with three dying.  Therefore, 5 of the 21 deaths 
in non-MDR-TB patients, or almost one quarter, involved subsequent development of 
drug resistant tuberculosis. As later sputum DST were not available for most patients, 
additional initially drug sensitive patients could well have acquired drug resistant TB. 
Therefore this figure is a lower limit for the contribution of drug resistant TB to mortality 
in patients presenting with non-MDR-TB.
Observed Drug Resistance Patterns and Changes in Resistance
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Eighty-nine percent of non-MDR isolates were fully susceptible; only seven (9%) 
isolates were mono-resistant and just one (1%) had poly-resistance.  No ethambutol 
(EMB), streptomycin (SM), kanamycin (KM) or ciprofloxacin (CPX) mono-resistant 
strains were found.  Several small studies have provided indirect and limited evidence 
that empiric use of quinolones, for pathogens and diseases unrelated to TB or to exclude a 
diagnosis of pneumonia in cases where a TB diagnosis is possible, may lead to acquired 
resistance of tuberculosis to quinolones (18-20).  The health governance in the 
Philippines, for example, has taken steps to limit the empiric use of quinolones citing this 
concern. However, in this study, there were no instances of monoresistance to 
ciprofloxacin.  Except in two isolates, CPX resistance was only seen in the context of 
KM resistance (likewise, except in 3 isolates, KM resistance was only seen along with 
CPX resistance), suggesting that primary transmission of a strain with resistance to both 
drugs, rather than empiric use of either drug, is responsible for resistance seen in this 
setting.
The predominance of SM-resistant strains among MDR-TB isolates, particularly 
in light of the fact that few patients received SM, suggests that primary (transmitted) drug 
resistance accounted for much—perhaps the majority—of MDR-TB in this population.  
This was evidenced among the small number of patients with multiple sputum isolates: 
seven patients with fully susceptible tuberculosis had MDR-TB with streptomycin 
resistance at a later date, and none had received SM during this period; this is strongly 
suggestive of primary, transmitted resistance.  In contrast, only one patient acquired INH 
and RIF resistance without acquiring SM resistance.  Moreover, one permutation—
resistance to INH, RIF, and SM—accounted for 60% of all (non-XDR) MDR-TB, 
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suggesting that a single drug resistant strain may be spreading quickly in this population, 
perhaps the result of a relative fitness.  Genetic analysis (e.g. spoligotyping, restriction 
fragment length polymorphism) is planned and may further clarify the genetic similarity 
of these isolates.
Only one patient had an initial isolate of MDR-TB and subsequent isolate of 
XDR-TB; this patient had exposure to second line drugs for five months between the 
collection of the two isolates, making it possible that this change represented 
amplification of resistance.
Among XDR-TB strains, there was heterogeneity of resistance patterns found.  
The most frequently observed strain (resistance to all six drugs) accounted for less than 
half (42.5%) of all isolates.  It is therefore likely that multiple XDR strains with varying 
resistance patterns are circulating in this setting; while amplification of resistance among 
XDR patients was not observed in this study, it is likely to happen when XDR patients 
with EMB or SM susceptibility are exposed to first line or re-treatment therapy 
(including SM) for long durations.  A subset of patients with resistance to all six drugs 
had DST performed for pyrazinamide, and PZA-resistance was observed (119). First line 
therapy or re-treatment therapy used in patients with XDR-TB may thus contain at most 
only one or two active drugs, which may result in the development of resistance to these 
agents.  Early identification of XDR-TB patients is thus particularly crucial for the 
preservation of these agents for use in combination with SLD.
Study Limitations
There were several important limitations to this study.  Many of these stemmed 
from the fact that this was a retrospective study in a resource-limited setting based on 
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chart review; as such, a limited number of charts were available and important data was 
missing from many charts and other data sources.  
Analysis of clinical predictors of drug resistance was limited by missing data for 
variables identified as potential predictors, including previous TB treatment outcomes, 
weight changes over the initial months of treatment, two month sputum smear, baseline 
chest radiograph and two month chest radiograph.  Because of the lack of differences in 
many baseline clinical characteristics, close examination of these clinical predictors in the 
initial period of TB treatment may provide more useful tools for distinguishing drug 
susceptible from drug resistant TB.  Such data would be more systematically obtained 
through prospective investigation.
The second major limitation of the study was the short follow-up period and lack 
of TB outcomes data for non-MDR-TB patients, both of which may have biased the 
mortality analyses (underestimating mortality in this group by failing to include patients 
who died at home or elsewhere); this data is currently being collected for patients from 
this group.  However, given that the mortality among this group was very similar to the 
literature value for TB among patients with untreated HIV disease, it is unlikely that 
mortality among these patients was significantly underestimated.
A third limitation is that aminoglycoside and fluoroquinolone use for reasons 
other than tuberculosis therapy were not recorded in the database.  It is possible that 
exposure to these drugs for other purposes impacted resistance; however, given the 
absence of observed monoresistance for SM, KM or CPX, it is unlikely that short-term 
exposure to fluoroquinolones or aminoglycosides played a large role in TB drug 
resistance in this setting.
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Drug susceptibility testing by the proportions method is subject to false positives 
and false negatives; most laboratories report an error of around 1-3% due to variations in 
performance and interpretation of the test, making clinical judgment an important factor 
in determining management of drug resistant TB patients.  The laboratory reporting 
results for this study underwent weekly external quality assessment as described in the 
Methods; the risk of cross contamination affecting results was therefore limited.
While assumptions can be made about the role of transmitted drug resistance 
among MDR-TB and XDR-TB patients in this study given the findings of resistance to 
drugs in the absence of their exposure, genotype data will further clarify the 
epidemiology and solidify these findings.  Genotyping is underway and analysis of the 
results with reference to this clinical data is planned.
The final important limitation of these related to the assignment of patients into 
TB categories.  Four patients in the MDR-TB only group and five patients in the XDR 
group had non-MDR-TB isolates only at the time of TB diagnosis. For clinical predictors 
and calculations of survival from the time of TB diagnosis, these patients may have been 
more similar to non-MDR patients than to other MDR only or XDR patients.  We felt it 
was important not to exclude these patients or reassign them to the non-MDR-TB group 
as they were not selected randomly like the non-MDR-TB group and therefore would 
have biased outcomes of that group.  Additionally, excluding them from the MDR-TB 
and XDR-TB group would remove all patients with prior fully susceptible TB, biasing 
those groups away from transmitted resistance.  Moreover, it is possible that these 
patients had mixed infection at the time of diagnosis and under first-line therapy, the drug 
susceptible strain was suppressed; mixed infections at the time of diagnosis were very 
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common—ten patients had isolates at the time of diagnosis belonging to two drug 
resistance groups (more may have been mixed infections in which both strains were not 
isolated).  
Despite these limitations, this represents the largest study of clinical 
characteristics of drug-resistant tuberculosis in a HIV prevalence setting, and many 
important observations emerged.  Larger, prospective studies are needed to confirm and 
clarify these findings.
Conclusion
The results of this study indicate that MDR-TB and XDR-TB carry a high 
mortality in this high HIV-prevalence setting.  Because patients did not have prior 
exposure to SLD and  the majority of XDR-TB patients had no previous TB treatment, 
this study adds evidence to our previous report suggesting that XDR-TB in this setting 
was predominantly, if not entirely, the result of primary, transmitted drug resistance. 
Moreover, these results suggest that primary MDR-TB is responsible for much—if not 
the majority—of MDR-TB in this setting, as well. The median survival for both MDR 
and XDR-TB patients in this study was approximately three months from TB diagnosis 
and two to three weeks from sputum collection. This short period leaves only a small 
window for identification of drug resistance and intervention. Further, the majority of 
patients are admitted to large, common TB wards before drug resistance diagnosis is 
made. Thus large numbers of patients are exposed to drug resistant organisms while 
hospitalized. Together, these highlight the critical need for improved infection control 
and clinical and laboratory tools for the early recognition of drug resistant TB. These 
include rapid culture and resistance testing techniques and clinical algorithms.  Although 
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much attention is now focused on the development of sophisticated molecular diagnostics 
for drug resistance, these are expensive and will likely remain unavailable for most 
patients in Sub-Saharan Africa. Moreover, currently few sites in Africa can perform DST 
in the conventional manner, with attendant delay in results. Therefore, further research is 
needed to elucidate clinical predictors of drug resistant TB, which may help with 
targeting DST and could result in early identification and treatment in drug resistant 
patients.  We hope that the current work is a step in the development of such procedures. 
70
REFERENCES
1. WHO. World Health Report 2004: Changing History. Geneva: World Health 
Organization, 2004.
2. WHO. Global tuberculosis control: surveillance, planning, financing. WHO 
Report 2006. Geneva, World Health Organization (WHO/HTM/TB/2006.362).
3. Murray, J.F. 2001. A thousand years of pulmonary medicine: good news and bad. 
European Respiratory Journal 17:558-565.
4. Lawn, S.D., Bekker, L.G., Middelkoop, K., Myer, L., and Wood, R. 2006. Impact 
of HIV infection on the epidemiology of tuberculosis in a peri-urban community 
in South Africa: the need for age-specific interventions. Clin Infect Dis 42:1040-
1047.
5. Corbett, E.L., Watt, C.J., Walker, N., Maher, D., Williams, B.G., Raviglione, 
M.C., and Dye, C. 2003. The growing burden of tuberculosis: global trends and 
interactions with the HIV epidemic. Archives of Internal Medicine 163:1009-
1021.
6. Corbett, E.L., Marston, B., Churchyard, G.J., and De Cock, K.M. 2006. 
Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the 
era of antiretroviral treatment. Lancet 367:926-937.
7. Fox, W., Ellard, G.A., and Mitchison, D.A. 1999. Studies on the treatment of 
tuberculosis undertaken by the British Medical Research Council tuberculosis 
units, 1946-1986, with relevant subsequent publications. International Journal of 
Tuberculosis & Lung Disease 3:S231-279.
8. Wolinksy, E., Reginster, A., and Steenken, W. 1948. Drug resistant tubercle 
bacilli in patients under treatment with streptomycin. American Review of 
Tuberculosis 58:335.
9. 1949. Medical Research Council: Treatment of pulmonary tuberculosis with 
streptomycin and para-aminosalicylic acid. British Medical Journal 2:1521-1525.
10. 1955. Medical Research Council: Various combinations of isoniazid with 
streptomycin or with PAS in the treatment of pulmonary tuberculosis. British 
Medical Journal 7:435-445.
11. Rich, M. 2006. Diagnosis and Treatment of Multidrug-Resistant Tuberculosis. In 
Tuberculosis: A Comprehensive, International Approach. M.C. Raviglione, 
editor. New York: Informa Healthcare USA, Inc. 417-458.
12. Colangeli, R., Helb, D., Sridharan, S., Sun, J., Varma-Basil, M., Hazbon, M.H., 
Harbacheuski, R., Megjugorac, N.J., Jacobs, W.R., Jr., Holzenburg, A., et al. 
2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an 
efflux pump that confers drug tolerance to both isoniazid and ethambutol. 
Molecular Microbiology 55:1829-1840.
13. Brennan, P.J., and Nikaido, H. 1995. The envelope of mycobacteria. Annual 
Review of Biochemistry 64:29-63.
14. Warner, D.F., and Mizrahi, V. 2006. Tuberculosis chemotherapy: the influence of 
bacillary stress and damage response pathways on drug efficacy. Clinical 
Microbiology Reviews 19:558-570.
71
15. 1952. Medical Research Council. Treatment of pulmonary tuberculosis with 
isoniazid; an interim report to the Medical Research Council by their Tuberculosis 
Chemotherapy Trials Committee. Br Med J 2:735-746.
16. Farmer, P., Robin, S., Ramilus, S.L., and Kim, J.Y. 1991. Tuberculosis, poverty, 
and "compliance": lessons from rural Haiti. Seminars in Respiratory Infections
6:254-260.
17. Farmer, P. 1997. Social scientists and the new tuberculosis.[see comment]. Social 
Science & Medicine 44:347-358.
18. Ginsburg, A.S., Grosset, J.H., and Bishai, W.R. 2003. Fluoroquinolones, 
tuberculosis, and resistance. The Lancet Infectious Diseases 3:432-442.
19. Sterling, T.R. 2004. The WHO/IUATLD diagnostic algorithm for tuberculosis 
and empiric fluoroquinolone use: potential pitfalls. International Journal of 
Tuberculosis & Lung Disease 8:1396-1400.
20. Grimaldo, E.R., Tupasi, T.E., Rivera, A.B., Quelapio, M.I., Cardano, R.C., 
Derilo, J.O., and Belen, V.A. 2001. Increased resistance to ciprofloxacin and 
ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from 
patients seen at a tertiary hospital in the Philippines.[see comment]. International 
Journal of Tuberculosis & Lung Disease 5:546-550.
21. Bishai, W.R., Graham, N.M., Harrington, S., Page, C., Moore-Rice, K., Hooper, 
N., and Chaisson, R.E. 1996. Brief report: rifampin-resistant tuberculosis in a 
patient receiving rifabutin prophylaxis. New England Journal of Medicine
334:1573-1576.
22. Ridzon, R., Whitney, C.G., McKenna, M.T., Taylor, J.P., Ashkar, S.H., Nitta, 
A.T., Harvey, S.M., Valway, S., Woodley, C., Cooksey, R., et al. 1998. Risk 
factors for rifampin mono-resistant tuberculosis. American Journal of Respiratory 
& Critical Care Medicine 157:1881-1884.
23. 2003. Partners in Health. The PIH Guide to Medical Management of Multidrug-
Resistant Tuberculosis. Boston: Partners in Health.
24. 2006. World Health Organization.  Guidelines for the Programmatic Management 
of Drug-Resistant Tuberculosis. Geneva: WHO.
25. Meier, A., Sander, P., Schaper, K.J., Scholz, M., and Bottger, E.C. 1996. 
Correlation of molecular resistance mechanisms and phenotypic resistance levels 
in streptomycin-resistant Mycobacterium tuberculosis. Antimicrobial Agents & 
Chemotherapy 40:2452-2454.
26. Cegielski, P., Blondal-Vink, K., Lambregts-van Weezenbeek, K., and Jaramillo, 
E. 2006. Programmatic Control of Multidrug-Resistant Tuberculosis. In 
Tuberculosis: A Comprehensive, International Approach. M.C. Raviglione, 
editor. New York: Informa Healthcare USA, Inc. 845-868.
27. Pearson, M.L., Jereb, J.A., Frieden, T.R., Crawford, J.T., Davis, B.J., Dooley, 
S.W., and Jarvis, W.R. 1992. Nosocomial transmission of multidrug-resistant 
Mycobacterium tuberculosis. A risk to patients and health care workers.[see 
comment]. Annals of Internal Medicine 117:191-196.
28. Frieden, T.R., Sterling, T., Pablos-Mendez, A., Kilburn, J.O., Cauthen, G.M., and 
Dooley, S.W. 1993. The emergence of drug-resistant tuberculosis in New York 
City.[see comment][erratum appears in N Engl J Med 1993 Jul 8;329(2):148]. 
New England Journal of Medicine 328:521-526.
72
29. Centers for Disease, C. 1990. Nosocomial transmission of multidrug-resistant 
tuberculosis to health-care workers and HIV-infected patients in an urban 
hospital--Florida. MMWR - Morbidity & Mortality Weekly Report 39:718-722.
30. Centers for Disease, C. 1990. Outbreak of multidrug-resistant tuberculosis--
Texas, California, and Pennsylvania. MMWR - Morbidity & Mortality Weekly 
Report 39:369-372.
31. Moss, A.R., Alland, D., Telzak, E., Hewlett, D., Jr., Sharp, V., Chiliade, P., 
LaBombardi, V., Kabus, D., Hanna, B., Palumbo, L., et al. 1997. A city-wide 
outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in 
New York. International Journal of Tuberculosis & Lung Disease 1:115-121.
32. Frieden, T.R., Fujiwara, P.I., Washko, R.M., and Hamburg, M.A. 1995. 
Tuberculosis in New York City--turning the tide. New England Journal of 
Medicine 333:229-233.
33. Moro, M.L., Gori, A., Errante, I., Infuso, A., Franzetti, F., Sodano, L., and Iemoli, 
E. 1998. An outbreak of multidrug-resistant tuberculosis involving HIV-infected 
patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis 
Outbreak Study Group. AIDS 12:1095-1102.
34. Centers for Disease Control and, P. 1996. Multidrug-resistant tuberculosis 
outbreak on an HIV ward--Madrid, Spain, 1991-1995. MMWR - Morbidity & 
Mortality Weekly Report 45:330-333.
35. Centers for Disease Control and, P. 1999. Primary multidrug-resistant 
tuberculosis--Ivanovo Oblast, Russia, 1999. MMWR - Morbidity & Mortality 
Weekly Report 48:661-664.
36. Ritacco, V., Di Lonardo, M., Reniero, A., Ambroggi, M., Barrera, L., Dambrosi, 
A., Lopez, B., Isola, N., and de Kantor, I.N. 1997. Nosocomial spread of human 
immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos
Aires.[see comment]. Journal of Infectious Diseases 176:637-642.
37. WHO. Anti-tuberculosis drug resistance in the world: third global report. 
WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance 
Surveillance. Geneva, 2004. (WHO/HTM/TB/2004.343).
38. Aziz, M.A., Wright, A., Laszlo, A., De Muynck, A., Portaels, F., Van Deun, A., 
Wells, C., Nunn, P., Blanc, L., Raviglione, M., et al. 2006. Epidemiology of 
antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug 
Resistance Surveillance): an updated analysis. Lancet 368:2142-2154.
39. Centers for Disease Control and, P. 2006. Emergence of Mycobacterium 
tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-
2004. MMWR - Morbidity & Mortality Weekly Report 55:301-305.
40. Masjedi, M.R., Farnia, P., Sorooch, S., Pooramiri, M.V., Mansoori, S.D., Zarifi, 
A.Z., Akbarvelayati, A., and Hoffner, S. 2006. Extensively drug-resistant 
tuberculosis: 2 years of surveillance in Iran. Clinical Infectious Diseases 43:841-
847.
41. Gandhi, N.R., Moll, A., Sturm, A.W., Pawinski, R., Govender, T., Lalloo, U., 
Zeller, K., Andrews, J., and Friedland, G. 2006. Extensively drug-resistant 
tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV 
in a rural area of South Africa.[see comment]. Lancet 368:1575-1580.
73
42. DeRiemer, K., Garcia-Garcia, L., Bobadilla-del-Valle, M., Palacios-Martinez, M., 
Martinez-Gamboa, A., Small, P.M., Sifuentes-Osornio, J., and Ponce-de-Leon, A. 
2005. Does DOTS work in populations with drug-resistant tuberculosis?[see 
comment]. Lancet 365:1239-1245.
43. Farmer, P., Bayona, J., Becerra, M., Furin, J., Henry, C., Hiatt, H., Kim, J.Y., 
Mitnick, C., Nardell, E., and Shin, S. 1998. The dilemma of MDR-TB in the 
global era.[see comment][comment]. International Journal of Tuberculosis & 
Lung Disease 2:869-876.
44. Anuradha, B., Aparna, S., Hari Sai Priya, V., Vijaya Lakshmi, V., Akbar, Y., 
Suman Latha, G., and Murthy, K.J.R. 2006. Prevalence of drug resistance under 
the DOTS strategy in Hyderabad, South India, 2001-2003.[erratum appears in Int 
J Tuberc Lung Dis. 2006 Jun;10(6):708 Note: Priya, VHS [corrected to Hari Sai 
Priya, V]; Lakshmi, VV [corrected to Vijaya Lakshmi, V]; Latha, GS [corrected 
to Suman Latha, G]]. International Journal of Tuberculosis & Lung Disease
10:58-62.
45. Espinal, M.A., Kim, S.J., Suarez, P.G., Kam, K.M., Khomenko, A.G., Migliori, 
G.B., Baez, J., Kochi, A., Dye, C., and Raviglione, M.C. 2000. Standard short-
course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 
countries.[see comment]. JAMA 283:2537-2545.
46. Rigouts, L., and Portaels, F. 1994. DNA fingerprints of Mycobacterium 
tuberculosis do not change during the development of resistance to various 
antituberculous drugs.[comment]. Tubercle & Lung Disease 75:160.
47. Portaels, F., Rigouts, L., Shamputa, I., Van Deun, A., and Abdel Aziz, M. 2006. 
Tuberculosis Drug Resistance in the World. In Tuberculosis: A Comprehensive, 
International Approach. M.C. Raviglione, editor. New York: Informa Healthcare
USA, Inc. 823-844.
48. Blower, S.M., and Chou, T. 2004. Modeling the emergence of the 'hot zones': 
tuberculosis and the amplification dynamics of drug resistance. Nature Medicine
10:1111-1116.
49. Yong Kim, J., Shakow, A., Mate, K., Vanderwarker, C., Gupta, R., and Farmer, P. 
2005. Limited good and limited vision: multidrug-resistant tuberculosis and 
global health policy. Social Science & Medicine 61:847-859.
50. 1999. Harvard Medical School / Open Society Institute. The Global Impact of 
Drug Resistant Tuberculosis. Boston: Program in Infectious Disease and Social 
Change, Harvard Medical School.
51. Gupta, R., Cegielski, J.P., Espinal, M.A., Henkens, M., Kim, J.Y., Lambregts-Van 
Weezenbeek, C.S.B., Lee, J.-W., Raviglione, M.C., Suarez, P.G., and Varaine, F.
2002. Increasing transparency in partnerships for health--introducing the Green 
Light Committee. Tropical Medicine & International Health 7:970-976.
52. Friedland, G.H. 2007. Tuberculosis, drug resistance, and HIV/AIDS: a triple 
threat. Clin Infect Dis Rep In Press.
53. Weyer, K., and Kleeberg, H.H. 1992. Primary and acquired drug resistance in 
adult black patients with tuberculosis in South Africa: results of a continuous 
national drug resistance surveillance programme involvement. Tubercle & Lung 
Disease 73:106-112.
74
54. Weyer, K., Groenewald, P., Zwarenstein, M., and Lombard, C.J. 1995. 
Tuberculosis drug resistance in the Western Cape. South African Medical Journal 
Suid-Afrikaanse Tydskrif Vir Geneeskunde 85:499-504.
55. Weyer, K., Lancaster, J., Balt, E., and Durrheim, D. 1998. Tuberculosis drug 
resistance in Mpumalanga province, South Africa. In: Proceedings of the Global 
Congress on Lung Health, 29th World Conference of the International Union 
Against Tuberculosis and Lung Disease, Bangkok, Thailand, 23-26 November. 
Int J Tuberc Lung Dis 2:S165.
56. Wilkinson, D., Pillay, M., Davies, G.R., and Sturm, A.W. 1996. Resistance to 
antituberculosis drugs in rural South Africa: rates, patterns, risks, and 
transmission dynamics. Transactions of the Royal Society of Tropical Medicine & 
Hygiene 90:692-695.
57. Davies, G.R., Pillay, M., Sturm, A.W., and Wilkinson, D. 1999. Emergence of 
multidrug-resistant tuberculosis in a community-based directly observed 
treatment programme in rural South Africa. International Journal of Tuberculosis 
& Lung Disease 3:799-804.
58. Weyer, K., Lancaster, J., Brand, J., van der Walk, M., and Levin, J. 2004. Survey 
of Tuberculosis Drug Resistance in South Africa: 2001-2002. Pretoria: Medical 
Research Council of South Africa.
59. Centers for Disease Control and, P. 2006. Trends in tuberculosis--United States, 
2005. MMWR - Morbidity & Mortality Weekly Report 55:305-308.
60. 2006. Case definition for extensively drug-resistant tuberculosis. Weekly 
Epidemiological Record 81:408.
61. 2006. Addressing the threat of tuberculosis caused by extensively drug-resistant 
Mycobacterium tuberculosis. Weekly Epidemiological Record 81:386-390.
62. 2006. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for 
prevention and control. Weekly Epidemiological Record 81:430-432.
63. Boulahbal, F., and Heifets, L. 2006. Bacteriology of Tuberculosis. In 
Tuberculosis: A Comprehensive, International Approach. M.C. Raviglione, 
editor. New York: Informa Healthcare USA, Inc. 29-46.
64. Moore, D.A.J., Evans, C.A.W., Gilman, R.H., Caviedes, L., Coronel, J., Vivar, 
A., Sanchez, E., Pinedo, Y., Saravia, J.C., Salazar, C., et al. 2006. Microscopic-
observation drug-susceptibility assay for the diagnosis of TB.[see comment]. New 
England Journal of Medicine 355:1539-1550.
65. Kim, S.J., Espinal, M.A., Abe, C., Bai, G.H., Boulahbal, F., Fattorin, L., Gilpin, 
C., Hoffner, S., Kam, K.M., Martin-Casabona, N., et al. 2004. Is second-line anti-
tuberculosis drug susceptibility testing reliable? International Journal of 
Tuberculosis & Lung Disease 8:1157-1158.
66. Kim, S.J. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability 
of results. European Respiratory Journal 25:564-569.
67. Casal, M., Vaquero, M., Rinder, H., Tortoli, E., Grosset, J., Rusch-Gerdes, S., 
Gutierrez, J., and Jarlier, V. 2005. A case-control study for multidrug-resistant 
tuberculosis: risk factors in four European countries. Microbial Drug Resistance-
Mechanisms Epidemiology & Disease 11:62-67.
75
68. El Sahly, H.M., Teeter, L.D., Pawlak, R.R., Musser, J.M., and Graviss, E.A. 2006. 
Drug-resistant tuberculosis: a disease of target populations in Houston, Texas. 
Journal of Infection 53:5-11.
69. Conaty, S.J., Hayward, A.C., Story, A., Glynn, J.R., Drobniewski, F.A., and 
Watson, J.M. 2004. Explaining risk factors for drug-resistant tuberculosis in 
England and Wales: contribution of primary and secondary drug resistance. 
Epidemiology & Infection 132:1099-1108.
70. Pritchard, A.J., Hayward, A.C., Monk, P.N., and Neal, K.R. 2003. Risk factors for
drug resistant tuberculosis in Leicestershire--poor adherence to treatment remains 
an important cause of resistance. Epidemiology & Infection 130:481-483.
71. Sandman, L., Schluger, N.W., Davidow, A.L., and Bonk, S. 1999. Risk factors for 
rifampin-monoresistant tuberculosis: A case-control study. American Journal of 
Respiratory & Critical Care Medicine 159:468-472.
72. Mannheimer, S.B., Sepkowitz, K.A., Stoeckle, M., Friedman, C.R., Hafner, A., 
and Riley, L.W. 1997. Risk factors and outcome of human immunodeficiency 
virus-infected patients with sporadic multidrug-resistant tuberculosis in New York 
City. International Journal of Tuberculosis & Lung Disease 1:319-325.
73. Faustini, A., Hall, A.J., and Perucci, C.A. 2006. Risk factors for multidrug 
resistant tuberculosis in Europe: a systematic review. Thorax 61:158-163.
74. Telzak, E.E., Chirgwin, K.D., Nelson, E.T., Matts, J.P., Sepkowitz, K.A., Benson, 
C.A., Perlman, D.C., and El-Sadr, W.M. 1999. Predictors for multidrug-resistant 
tuberculosis among HIV-infected patients and response to specific drug regimens. 
Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and 
the AIDS Clinical Trials Group (ACTG), National Institutes for Health. 
International Journal of Tuberculosis & Lung Disease 3:337-343.
75. Cohn, M., Oda, U., Kovitz, C., and Middlebrook, G. 1954. Studies on isoniazid 
and tubercle bacilli. I. The isolation of
isoniazid-resistant mutants in vitro. American Review of Tuberculosis 70:465-475.
76. Cohn, M., Kovitz, C., Oda, U., and Middlebrook, G. 1954. Studies on isoniazid 
and tubercle bacilli. II. The growth requirements, catalase activities, and 
pathogenic properties of isoniazid-resistant mutants. American Review of 
Tuberculosis 70:641-664.
77. Garcia-Garcia, M.L., Ponce de Leon, A., Jimenez-Corona, M.E., Jimenez-Corona, 
A., Palacios-Martinez, M., Balandrano-Campos, S., Ferreyra-Reyes, L., Juarez-
Sandino, L., Sifuentes-Osornio, J., Olivera-Diaz, H., et al. 2000. Clinical 
consequences and transmissibility of drug-resistant tuberculosis in southern 
Mexico.[see comment]. Archives of Internal Medicine 160:630-636.
78. Burgos, M., DeRiemer, K., Small, P.M., Hopewell, P.C., and Daley, C.L. 2003. 
Effect of drug resistance on the generation of secondary cases of tuberculosis.[see 
comment]. Journal of Infectious Diseases 188:1878-1884.
79. Frieden, T.R., Sherman, L.F., Maw, K.L., Fujiwara, P.I., Crawford, J.T., Nivin, 
B., Sharp, V., Hewlett, D., Jr., Brudney, K., Alland, D., et al. 1996. A multi-
institutional outbreak of highly drug-resistant tuberculosis: epidemiology and 
clinical outcomes.[see comment]. JAMA 276:1229-1235.
80. Snider, D.E., Jr., Kelly, G.D., Cauthen, G.M., Thompson, N.J., and Kilburn, J.O. 
1985. Infection and disease among contacts of tuberculosis cases with drug-
76
resistant and drug-susceptible bacilli. American Review of Respiratory Disease
132:125-132.
81. Gordin, F.M., Nelson, E.T., Matts, J.P., Cohn, D.L., Ernst, J., Benator, D., Besch, 
C.L., Crane, L.R., Sampson, J.H., Bragg, P.S., et al. 1996. The impact of human 
immunodeficiency virus infection on drug-resistant tuberculosis. American 
Journal of Respiratory & Critical Care Medicine 154:1478-1483.
82. Campos, P.E., Suarez, P.G., Sanchez, J., Zavala, D., Arevalo, J., Ticona, E., 
Nolan, C.M., Hooton, T.M., and Holmes, K.K. 2003. Multidrug-resistant 
Mycobacterium tuberculosis in HIV-infected persons, Peru. Emerging Infectious 
Diseases 9:1571-1578.
83. Punnotok, J., Shaffer, N., Naiwatanakul, T., Pumprueg, U., Subhannachart, P., 
Ittiravivongs, A., Chuchotthaworn, C., Ponglertnapagorn, P., Chantharojwong, N., 
Young, N.L., et al. 2000. Human immunodeficiency virus-related tuberculosis 
and primary drug resistance in Bangkok, Thailand. International Journal of 
Tuberculosis & Lung Disease 4:537-543.
84. Kenyon, T.A., Mwasekaga, M.J., Huebner, R., Rumisha, D., Binkin, N., and 
Maganu, E. 1999. Low levels of drug resistance amidst rapidly increasing 
tuberculosis and human immunodeficiency virus co-epidemics in Botswana.[see 
comment]. International Journal of Tuberculosis & Lung Disease 3:4-11.
85. Churchyard, G.J., Corbett, E.L., Kleinschmidt, I., Mulder, D., and De Cock, K.M. 
2000. Drug-resistant tuberculosis in South African gold miners: incidence and 
associated factors. International Journal of Tuberculosis & Lung Disease 4:433-
440.
86. Espinal, M.A., Laserson, K., Camacho, M., Fusheng, Z., Kim, S.J., Tlali, R.E., 
Smith, I., Suarez, P., Antunes, M.L., George, A.G., et al. 2001. Determinants of 
drug-resistant tuberculosis: analysis of 11 countries.[see comment]. International 
Journal of Tuberculosis & Lung Disease 5:887-893.
87. Munsiff, S.S., Joseph, S., Ebrahimzadeh, A., and Frieden, T.R. 1997. Rifampin-
monoresistant tuberculosis in New York City, 1993-1994. Clinical Infectious 
Diseases 25:1465-1467.
88. Berning, S.E., Huitt, G.A., Iseman, M.D., and Peloquin, C.A. 1992. 
Malabsorption of antituberculosis medications by a patient with AIDS. New 
England Journal of Medicine 327:1817-1818.
89. Peloquin, C.A., MacPhee, A.A., and Berning, S.E. 1993. Malabsorption of 
antimycobacterial medications. New England Journal of Medicine 329:1122-
1123.
90. Patel, K.B., Belmonte, R., and Crowe, H.M. 1995. Drug malabsorption and 
resistant tuberculosis in HIV-infected patients. New England Journal of Medicine
332:336-337.
91. Chaisson, R.E., Clermont, H.C., Holt, E.A., Cantave, M., Johnson, M.P., 
Atkinson, J., Davis, H., Boulos, R., Quinn, T.C., and Halsey, N.A. 1996. Six-
month supervised intermittent tuberculosis therapy in Haitian patients with and 
without HIV infection. American Journal of Respiratory & Critical Care 
Medicine 154:1034-1038.
77
92. Harries, A.D., Hargreaves, N.J., Kemp, J., Jindani, A., Enarson, D.A., Maher, D., 
and Salaniponi, F.M. 2001. Deaths from tuberculosis in sub-Saharan African 
countries with a high prevalence of HIV-1.[see comment]. Lancet 357:1519-1523.
93. Murray, J., Sonnenberg, P., Shearer, S.C., and Godfrey-Faussett, P. 1999. Human 
immunodeficiency virus and the outcome of treatment for new and recurrent 
pulmonary tuberculosis in African patients. American Journal of Respiratory & 
Critical Care Medicine 159:733-740.
94. Kawai, V., Soto, G., Gilman, R.H., Bautista, C.T., Caviedes, L., Huaroto, L., 
Ticona, E., Ortiz, J., Tovar, M., Chavez, V., et al. 2006. Tuberculosis mortality, 
drug resistance, and infectiousness in patients with and without HIV infection in 
Peru. Am J Trop Med Hyg 75:1027-1033.
95. Fischl, M.A., Daikos, G.L., Uttamchandani, R.B., Poblete, R.B., Moreno, J.N., 
Reyes, R.R., Boota, A.M., Thompson, L.M., Cleary, T.J., Oldham, S.A., et al. 
1992. Clinical presentation and outcome of patients with HIV infection and 
tuberculosis caused by multiple-drug-resistant bacilli. Annals of Internal Medicine
117:184-190.
96. Long, R., Scalcini, M., Manfreda, J., Jean-Baptiste, M., and Hershfield, E. 1991. 
The impact of HIV on the usefulness of sputum smears for the diagnosis of 
tuberculosis. American Journal of Public Health 81:1326-1328.
97. Johnson, J.L., Vjecha, M.J., Okwera, A., Hatanga, E., Byekwaso, F., Wolski, K., 
Aisu, T., Whalen, C.C., Huebner, R., Mugerwa, R.D., et al. 1998. Impact of 
human immunodeficiency virus type-1 infection on the initial bacteriologic and 
radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere 
University-Case Western Reserve University Research Collaboration. 
International Journal of Tuberculosis & Lung Disease 2:397-404.
98. Elliott, A.M., Namaambo, K., Allen, B.W., Luo, N., Hayes, R.J., Pobee, J.O., and 
McAdam, K.P. 1993. Negative sputum smear results in HIV-positive patients 
with pulmonary tuberculosis in Lusaka, Zambia. Tubercle & Lung Disease
74:191-194.
99. Greenberg, S.D., Frager, D., Suster, B., Walker, S., Stavropoulos, C., and 
Rothpearl, A. 1994. Active pulmonary tuberculosis in patients with AIDS: 
spectrum of radiographic findings (including a normal appearance). Radiology
193:115-119.
100. Palmieri, F., Girardi, E., Pellicelli, A.M., Rianda, A., Bordi, E., Rizzi, E.B., 
Petrosillo, N., and Ippolito, G. 2002. Pulmonary tuberculosis in HIV-infected 
patients presenting with normal chest radiograph and negative sputum smear. 
Infection 30:68-74.
101. Perlman, D.C., el-Sadr, W.M., Nelson, E.T., Matts, J.P., Telzak, E.E., Salomon, 
N., Chirgwin, K., and Hafner, R. 1997. Variation of chest radiographic patterns in 
pulmonary tuberculosis by degree of human immunodeficiency virus-related 
immunosuppression. The Terry Beirn Community Programs for Clinical Research 
on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clinical Infectious 
Diseases 25:242-246.
102. Post, F.A., Wood, R., and Pillay, G.P. 1995. Pulmonary tuberculosis in HIV 
infection: radiographic appearance is related to CD4+ T-lymphocyte count. 
Tubercle & Lung Disease 76:518-521.
78
103. Furin, J.J., Mitnick, C.D., Shin, S.S., Bayona, J., Becerra, M.C., Singler, J.M., 
Alcantara, F., Castanieda, C., Sanchez, E., Acha, J., et al. 2001. Occurrence of 
serious adverse effects in patients receiving community-based therapy for 
multidrug-resistant tuberculosis. International Journal of Tuberculosis & Lung 
Disease 5:648-655.
104. Torun, T., Gungor, G., Ozmen, I., Bolukbai, Y., Maden, E., Bicakci, B., Atac, G., 
Sevim, T., and Tahaolu, K. 2005. Side effects associated with the treatment of 
multidrug-resistant tuberculosis. International Journal of Tuberculosis & Lung 
Disease 9:1373-1377.
105. Nathanson, E., Gupta, R., Huamani, P., Leimane, V., Pasechnikov, A.D., Tupasi, 
T.E., Vink, K., Jaramillo, E., and Espinal, M.A. 2004. Adverse events in the 
treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus 
initiative. Int J Tuberc Lung Dis 8:1382-1384.
106. Mitnick, C., Bayona, J., Palacios, E., Shin, S., Furin, J., Alcantara, F., Sanchez, 
E., Sarria, M., Becerra, M., Fawzi, M.C.S., et al. 2003. Community-based therapy 
for multidrug-resistant tuberculosis in Lima, Peru. New England Journal of 
Medicine 348:119-128.
107. Nathanson, E., Lambregts-van Weezenbeek, C., Rich, M.L., Gupta, R., Bayona, 
J., Blondal, K., Caminero, J.A., Cegielski, J.P., Danilovits, M., Espinal, M.A., et 
al. 2006. Multidrug-resistant tuberculosis management in resource-limited 
settings. Emerging Infectious Diseases 12:1389-1397.
108. Drobniewski, F. 1997. Is death inevitable with multiresistant TB plus HIV 
infection?[see comment][erratum appears in Lancet 1997 Mar 15;349(9054):810]. 
Lancet 349:71-72.
109. van der Wal, M., Weyer, K., and Lancastre, J. 2006. A standardised approach to 
management of drug-resistant TB in South Africa. In South Africa Medical 
Research Council Expert Consultation on Drug-Resistant Tuberculosis. 
Johannesberg.
110. Leimane, V. 2006. MDR-TB and XDR-TB Management in Latvia. In Meeting of 
the Global XDR-TB Task Force. Geneva.
111. Resch, S.C., Salomon, J.A., Murray, M., and Weinstein, M.C. 2006. Cost-
effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3:e241.
112. Republic of South Africa Department of Health. 2000. The South African 
Tuberculosis Control Programme Practical Guidelines.
113. Migliori, G.B., Espinal, M., Danilova, I.D., Punga, V.V., Grzemska, M., and 
Raviglione, M.C. 2002. Frequency of recurrence among MDR-tB cases 
'successfully' treated with standardised short-course chemotherapy. International 
Journal of Tuberculosis & Lung Disease 6:858-864.
114. Rouillon, A., Perdrizet, S., and Parrot, R. 1976. Transmission of tubercle bacilli: 
The effects of chemotherapy. Tubercle 57:275-299.
115. Colebunders, R., and Bastian, I. 2000. A review of the diagnosis and treatment of 
smear-negative pulmonary tuberculosis. International Journal of Tuberculosis & 
Lung Disease 4:97-107.
116. Manosuthi, W., Chottanapand, S., Thongyen, S., Chaovavanich, A., and 
Sungkanuparph, S. 2006. Survival rate and risk factors of mortality among 
79
HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. 
Journal of Acquired Immune Deficiency Syndromes: JAIDS 43:42-46.
117. Lawn, S.D., Myer, L., Bekker, L.-G., and Wood, R. 2006. Burden of tuberculosis 
in an antiretroviral treatment programme in sub-Saharan Africa: impact on 
treatment outcomes and implications for tuberculosis control. AIDS 20:1605-
1612.
118. Harries, A.D., Nyangulu, D.S., Kang'ombe, C., Ndalama, D., Glynn, J.R., Banda, 
H., Wirima, J.J., Salaniponi, F.M., Liomba, G., Maher, D., et al. 1998. Treatment 
outcome of an unselected cohort of tuberculosis patients in relation to human 
immunodeficiency virus serostatus in Zomba Hospital, Malawi. Transactions of 
the Royal Society of Tropical Medicine & Hygiene 92:343-347.
119. Sturm, A.W. 2006. The UKZN "Outbreak". In Expert Consultation on XDR-TB. 
Johannesburg.
